Michael R. Liebowitz, M.D.

1/12/2012

 

Curriculum Vitae
Michael R. Liebowitz, M.D.
134 East 93rd Street, 2nd Floor
New York, New York 10128

 

Citizenship:
      United States of America

Education:
      9/65 - 6/69 - Yale University School of Medicine, M.D.  
      9/61 - 6/65 - Yale College, B.A. (Cum Laude)


Licensure Status:
      1971 - Present - New York 
      1977 - Present - New Jersey  


Internship Residency:
      7/75 - 6/77 - Psychiatric Residency, NYS Psychiatric Institute
      7/74 - 6/75 - Psychiatric Residency, Medical Center Hospital of Vermont
      7/70 - 6/71 - Medical Residency, Columbia Service, Harlem Hospital, New York
      7/69 - 6/70 - Rotating Internship, Harlem Hospital, New York
                                                                     

Fellowship:
      7/77 - 6/79 - Research Fellow, New York State Psychiatric Institute, New York

Board Certification:
      1978 - American Board Psychiatry and Neurology

Military Service:
      1972 - 1974 - Civilian Alternative Service
 

Academic Appointments
      7/90 – Present      Professor of Clinical Psychiatry  
 
                                   College of Physicians and Surgeons, Columbia University
      7/85 – 6/90          Associate Professor of Clinical Psychiatry  
 
                                   College of Physicians and Surgeons, Columbia University
      7/79 – 6/85           Assistant Professor of Clinical Psychiatry  
 
                                   College of Physicians and Surgeons, Columbia University
      7/77 – 6/79           Instructor in Clinical Psychiatry  
 
                                   College of Physicians and Surgeons, Columbia University

 Professional Societies:

      2000 – 09/06      American Psychopathological Association  
      1998 – 09/06       American Society of Clinical Psychopharmacology
      07/97
Present   Anxiety Disorders Association of America Scientific Advisory Board
      12/87
Present    American College of Neuropsychopharmacology
      04/87 – 09/06     Psychiatric Research Society
      07/77
Present   American Psychiatric Association
      1968
1972         Medical Committee for Human Rights

Hospital & Medical Staff Appointments:
      7/90 – 9/06        Director, Hispanic Treatment Program, NYS Psychiatric Institute
      7/90 – 9/09        Attending Psychiatrist, Columbia-Presbyterian Medical Center
      7/85 6/90        Associate Attending Psychiatrist, Columbia-Presbyterian Medical Center
      9/84 – 9/88        Consultant, Morristown Memorial Hospital, Morristown, N.J.
      7/82 – 9/06        Director, Anxiety Disorders Clinic, NYS Psychiatric Institute
      7/77 6/85         Assistant Attending Psychiatrist, Columbia Presbyterian Medical Center
      7/77 – 9/06         Research Psychiatrist, New York State Psychiatric Institute
      2/77 6/77         Consultant, Central Bergen Mental Health Center; Paramus, N.J.
      1/77 5/77          Part-time Physician, Rikers Island Correctional Facility; Queens, N.Y. 
      7/76 1/77          Part-time Psychiatrist, Washington Heights-West Harlem-Inwood Mental Health                                         Center, NY.
      1972 1974        Emergency Room Physician, Copley Hospital, Morrisville, Vermont
      1971 1972         OEO Project MD, East Nassau Medical Group, Nassau County, NY
      1970 1971         Inpatient Narcotics Detoxification Unit, Harlem Hospital, New York

Honors:
      2004  Scientific Contribution Award, Freedom From Fear
      1994   President, Psychiatric Research Society (1994-1995)
      1992   Elected to Fellowship in the American Psychiatric Association
      1987   Elected to Membership, Psychiatric Research Society
      1987   Elected to Membership, American College of Neuropsychopharmacology
      1987   Clinical Psychiatry Research Award, American Academy of Clinical Psychiatry
      1977   First Prize for Resident Paper, N.Y. District Branch, American Psychiatric Association
      1976   New York State Psychiatric Institute Resident Research Award
      1976   Second Prize for Resident Papers, N.Y. District Branch, American Psychiatric Association

Grant Support Past:

Principal Investigator-    CBT Augmentation of Paroxetine for Social Anxiety NIMH 1RO1                                                                  MHO64726-01A1, 08/15/03-05/31/07

Principal Investigator -   CBT Augmentation of SRI Pharmacotherapy in OCD NIMH 2ROI MH454436-8,                                        8/01/01-06/30/05

Principal Investigator -   Pharmacotherapy of Social Phobia NIMH 2 R10 MH40121, 12/1/94-11/30/01

Principal Investigator -   Long-Term Treatment of Social Phobia NIMH 1 R10 MH55165, 8/1/01-6/30/05

Principal Investigator -   Anxiety Diagnostic and Recruitment Center Section of NIMH MH30906,                                                    MHCRC - New York State Psychiatric Institute
                                       Program Director - Donald F. Klein, M.D., 8/1/94-7/31/99

Principal Investigator -   The Study of Ataque in Hispanic Populations Component of NIMH Program                                              Project Grant
                                       Program Director - Donald F. Klein, M.D., 5/1/94-4/30/97

Co-Investigator -            A Family Study of Obsessive-Compulsive Disorder NIMH 1R01 MH44175
                                       Principal Investigator - Abby Fyer, M.D., 9/1/93- 8/31/96

Principal Investigator -   Fluoxetine in Adolescent Obsessive Compulsive Disorder 1 RO1 MH46439-                                                01,8/1/90-7/31/93
                                       Also supported by Eli Lilly and Company.

Principal Investigator -   Chlorimipramine and Behavior Therapy in Obsessive-Compulsive Disorder
                                       1R10 MH454436-01A1, 8/1/90-3/31/95

Principal Investigator -    Intravenous Chlorimipramine in Obsessive-Compulsive Disorder FD-R-000374-                                         04, 9/30/91-9/29/94

Principal Investigator -    Intravenous Chlorimipramine in Obsessive-Compulsive Disorder FD-R 00374-                                           01-03,  9/30/88-9/29/91

Principal Investigator -     Anxiety Diagnostic and Recruitment Unit Section of NIMH MH30906, MHCRC                                         - New York State Psychiatric Institute
                                        Program Director - Donald F. Klein, M.D., 8/1/89-7/31/94

Principal Investigator -    Pharmacotherapy of Social Phobia NIMH 1 R10 MH40121, 9/1/88-8/1/93

Principal Investigator -     Pharmacotherapy of Social Phobia NIMH, 1 R01 MH40121, 9/1/84-8/30/88

Principal Investigator -     Psychobiology of Obsessive Compulsive Disorder IROI 43845-01A1, 9/1/89 -
                                             8/31/92

Principal Investigator -     NIMH - Administrative Supplement of Hispanic Anxiety Disorders Clinic

                                        Supplement to Psychobiology, Genetics and Treatment of Anxiety Disorders
                                        Program Director - Donald F. Klein, M.D., 10/1/91-9/30/92

Co-Principal Investigator -  Lowenstein Center for the Study of Disruptive Behavior in Children

                                           Principal Investigator - Gail Wasserman, Ph.D.
                                           Funded by the Lowenstein Foundation, 1992-1997 (1/15/92-6/30/93)

Co-Investigator -     A Family Study of Obsessive Compulsive Disorder

                                Principal Investigator  Abby Fyer, M.D. NIMH 1R29-MH44175, 5/1/89 3/31/92

Co-Principal Investigator          Pharmacology and Physiology of Panic Attacks and Project Director B            
                                          NIMH MH33422-07, 9/85-8/88

Co-Principal Investigator -        Psychobiology, Genetics, and Treatment of Anxiety Disorders
           
                                       NIMH MH37592, 9/83-8/87

Co-Principal Investigator-         Carbon Dioxide Challenge of Panic Disorder

                                                  Principal Investigator - Jack Gorman, M.D.
                                                  NIMH MH41778, 8/1/86 - 7/31/89

Co-Principal Investigator -        Phenelzine, Imipramine and Placebo in Atypical Depression

                                                  NIMH MH35297, 5/82-4/84.

Principal Investigator -              Biomedical Research Support Grant - 1981-1982, Allocation #903-E4970

                                                  Assessment and Psychosocial Impairment in Depressed Patients Post                                                       Drug Therapy

Principal Investigator -              Biomedical Research Support Grant - 1979-1980 Hysteroid Dysphoria
                                                      and Atypical Depression

Former Department and University Committees:

Chairperson            Review Process and Funding Subcommittee, Clinical Trials Advisory Committee,                                     Columbia Presbyterian Medical Center (1995)
Member                  Clinical Trials Advisory Committee, Columbia Presbyterian Medical Center (1998-
                                    2004)
Member                  Executive Committee: Department of Psychiatry, College of Physicians and
                                                Surgeons, Columbia University (1998-2006)
Member                  New York State Psychiatry Institute Resident Selection Committee (1992-1995)
Member                  Medical Executive Committee (1989), New York State Psychiatric Institute
Member                  Institutional Review Board (for research ethics), New York State Psychiatric Institute
                                 and Department of Psychiatry, Columbia University (1982-1985) 

Teaching Experience:

Supervisor:
      1979-1983    PGY II Residents, New York State Psychiatric Institute
      1983-1984    Advanced Psychopharmacology Training for Residents from Other Hospitals, New                                 York State Psychiatric Institute
      1983-1986    PGY III Residents Psychopharmacology Training Program, New York Psychiatric                                      Institute
      1994-2006   PGY III Residents Psychopharmacology Training Program, New York Psychiatric                                      Institute

Coordinator and Teacher:
      1986-Present PGY III Outpatient Psychopharmacology Course, New York State Psychiatric Institute

Lecturer:
      1985-1988    PGY II Psychopharmacology & Psychopathology Course, New York State Psychiatric          Institute

Preceptor:
      1985-2006    Training Program for Psychiatry Research Fellows, New York State Psychiatric Institute

Section Leader:
      1978-1979         Second Year Course on Psychiatry, College of Physicians and Surgeons, Columbia         University

Other Professional Activities:

  • Scientific Advisory Board Pherin Pharmaceuticals (2010-Present)
  • Chief Scientific Officer: ChiMatrix, L.L.C. (2002-June 2011)
  • Managing Director: The Medical Research Network, L.L.C. (1997-Present)
  • Member: DSM IV Task Force, American Psychiatric Association (1991-1994)
  • Chairman: DSM IV Work Group on Anxiety Disorders (1991-1994)
  • Member: Program Committee, APA NY District Branch (1981-1984)
  • DSM III-R Advisory Committee on Anxiety Disorders (1985-1987)
  • Editorial Board: Journal of Personality Disorders (1986-1989)
  • Editorial Board Journal of Anxiety Disorders (1986-2000)
  • Member: American Board of Psychiatry and Neurology, Part 1 (1988-1990)
  • Consultant: The Medical Letter on Drugs and Therapeutics (1990-1995)
  • Editorial Board: Depression and Anxiety (1994-present)
  • Former Consultant: Hispanic Research and Recruitment Center, Columbia University
  • Former Consultant: CINP Manual on Psychiatric Treatment in Primary Care
  • Former Consultant: The Expert Consensus Consortium on OCD

 

Reviewer:              

Archives of General Psychiatry, Journal of Nervous and Mental Disease Journal of Clinical Psychopharmacology, Psychiatry Research, American Journal of Psychiatry, Emergency Medicine, Journal of Clinical Psychiatry, Journal of Psychiatric Research, Psychosomatic Medicine, Journal of Hospital and Community Psychiatry, Journal of Abnormal Psychology Psychoneuroendocrinology, Psychosomatics, Biological Psychiatry, Journal of Neuropsychiatry & Clinical Neuroscience, Psychopharmacology, Depression and Anxiety
 

Grant Reviewer:    National Institute of Mental Health
                              U.S. Veterans Administration
                              Medical Research Council of Canada


Contributing                American College of Psychiatrists
Editor:                          Psychiatry Resident In-training Examination

Public Relations:   American Psychiatric Association
      Anxiety Disorders Clinic, New York State Psychiatric Institute


Fund Raising:
      Department of Psychiatry, College of Physicians & Surgeons, Columbia University

 
Scientific Advisory Boards:
      Obsessive Compulsive Foundation 1995-1998
      Anxiety Disorder Association of America 1996-Present
      Smith Klein Beecham Pharmaceutical Company 1998-2000
      Wyeth-Ayerst Pharmaceutical Company 2001
      Astra Zeneca 2006-present
      Jazz Pharmaceuticals 2008
      Zars Pharmaceuticals 2008


Patents and Copyrights:

  1. E. Salmán, M.R. Liebowitz, and I. Bhandari:  Method and System for Accepting Data Related to a Patient, United States Patent No. 101,830,656; filed in 2004, patent pending.
  2. M. R. Liebowitz: Copyright holder, Liebowitz Social Anxiety Scale (LSAS)
  3. M. R. Liebowitz, C. Warner-Masia, R. Gittleman-Klein: Copyright holders, Liebowitz Social Anxiety Scale for Children and Adolescents (LSAS-CA)


Publications - Peer Reviewed Articles:

  1. Liebowitz MR, Nuetzel E, Bowser A, Fyer A and Klein DF: Phenelzine and delusions of parasitosis.  American Journal of Psychiatry, 135(12): 1565-1566, 1978.
  2. Liebowitz MR:  Is borderline a distinct entity?  Schizophrenia Bulletin, 5(1): 23-38, 1979.
  3. Liebowitz MR, Stallone F, Dunner D, and Fieve RR:  Personality features of patients with primary affective disorder.  Acta Psychiatrica Scandinavica, 60:214-224, 1979.
  4. Liebowitz MR and Klein DF:  Assessment and treatment of phobic anxiety.  Journal of Clinical Psychiatry, 40:48 6-492, 1979.
  5. Stewart JW, Quitkin FM, Fyer AJ, Rifkin A, McGrath PJ, Liebowitz MR, Rosnick L and Klein DF:  Efficacy of desipramine in endogenomorphically depressed patients.  Journal of Affective Disorders, 2:165-176, 1980.
  6. Quitkin FM, McGrath PJ, Fyer AJ, Liebowitz MR, Stewart J, and Howard A: Monoamine oxidase inhibitors in bipolar endogenous depressives.  Journal of Clinical Psychopharmacology, 1(2): 70-74, 1981.
  7. McGrath PJ, Quitkin FM, Stewart JW, Liebowitz MR, Fyer AJ, and Davies SO:  An open clinical trial of mianserin.  American Journal of Psychiatry, 138(4): 530-532, 1981.
  8. Liebowitz MR, Quitkin FM, McGrath PJ, and Stewart JW:  Clinical prediction of MAOI responsivity.  Journal of Psychiatric Treatment and Evaluation, 3(5): 467-473, 1981.
  9. Liebowitz MR:  Newer uses for older psychotropic medications.  Hospital and Community Psychiatry, 33(4): 282-286, 1982.
  10. Karoum F, Chuang L, Eisler T, Calne DB, Liebowitz MR, Quitkin FM, Klein DF and Wyatt RJ:  Metabolism of (-) deprenyl to amphetamine and methamphetamine may be responsible for its therapeutic benefit:  A biochemical assessment.  Neurology, 32:503-509, 1982.
  11. Gorman JM, Levy G, Liebowitz MR, McGrath P, Appleby I, Dillon D, Davies SO, and Klein DF:  The effect of acute beta-adrenergic blockade on lactate-induced panic.  Archives of General Psychiatry, 40:1079-1082, 1983.
  12. Stewart JW, Quitkin FM, Liebowitz MR, McGrath PJ, Harrison WM and Klein DF:  Efficacy of desipramine in depressed outpatients.  Archives of General Psychiatry, 40:202-207, 1983.
  13. Stewart JW, Harrison W, Quitkin FM, and Liebowitz MR:  Phenelzine-induced pyridoxine efficiency.  Journal of Clinical Psychopharmacology, 4(4): 225-226, 1984.
  14. Gorman JM, Martinez J, Fyer AJ, Liebowitz MR, and Klein DF:  Hypoglycemia and panic attacks.  American Journal of Psychiatry, 141:101-102, 1984.
  15. Liebowitz MR, Fyer AJ, Gorman JM, Dillon D, Appleby I, Levy G, Anderson S, Levitt M, Palij M, Davies SO, and Klein DF: Lactate provocation of panic attacks: I. Clinical and behavioral findings.  Archives of General Psychiatry, 41:764-770, 1984.
  16. Quitkin FM, Liebowitz MR, Stewart JW, McGrath PJ, Harrison W, Rabkin JG and Davies SO:  L-Deprenyl in atypical depressives.  Archives of General Psychiatry, 41:777-781, 1984.
  17. Liebowitz MR, Quitkin FM, Stewart JW, McGrath PJ, Harrison W, Rabkin J, Tricamo E, Markowitz JS, and Klein DF:  Phenelzine versus imipramine in atypical depression: A preliminary report.  Archives of General Psychiatry, 41(7): 669-677, 1984.
  18. Karoum F, Potkin S, Chuang LW, Murphy DL, Liebowitz MR and Wyatt RJ: Phenylacetic acid excretion in schizophrenia and depression: The origins of PAA in man.  Biological Psychiatry, 19(2): 165-178, 1984.
  19. Liebowitz MR, Quitkin FM, Stewart JW, McGrath PJ, Harrison W, Rabkin JG, Tricamo E, Markowitz JS and Klein DF: Psychopharmacologic validation of atypical depression.  Journal of Clinical Psychiatry, 45(7): 22-25, 1984.
  20. Liebowitz MR, Gorman JM, Fyer AJ, Dillon DJ and Klein DF:  The effects of naloxone in patients with panic attacks.  American Journal of Psychiatry, 141(8): 995-997, 1984.
  21. Fyer AJ, Gorman JM, Liebowitz MR, Martinez J, Levitt M, Danielson E, and Klein DF:  Sodium lactate infusion, panic attacks and ionized calcium. Biological Psychiatry, 19(10): 1437-1447, 1984.
  22. Gorman JM, Askanazi J, Liebowitz MR, Fyer AJ, Stein J, Kinney JM and Klein DF:  Response to hyperventilation in a group of patients with panic disorder.  American Journal of Psychiatry, 141(7): 857-861, 1984.
  23. Harrison WM, Cooper TB, Stewart JW, Quitkin FM, McGrath PJ, Liebowitz MR, Rabkin JG, Markowitz JS and Klein DF:  The tyramine challenge test as a marker for melancholia.  Archives of General Psychiatry, 41(7): 681-685, 1984.
  24. Quitkin FM, Harrison W, Liebowitz MR, McGrath PJ, Rabkin JG, Stewart J, and Markowitz J:  Defining the boundaries of atypical depression.  Journal of Clinical Psychiatry, 45(7): 19-21, 1984.
  25. Stewart JW, Quitkin FQ, Liebowitz MR, McGrath PJ, Harrison W, Rabkin JG, Novacenko H, Puig-Antich J, and Anis G:  Cortisol response to dextroamphetamine stimulation in depressed outpatients.  Psychiatry Research, 12:195-206, 1984.
  26. Rabkin JG, McGrath PJ, Quitkin FM, Fyer AJ, Stewart JW, Liebowitz MR and Markowitz J: Mianserin versus amitriptyline for depression:  A double-blind 6-week trial.  Neuropsycho-biology, 12:224-228, 1984.
  27. Gorman JM, Liebowitz MR, Stein J, Fyer A and Klein DF:  Insulin levels during lactate infusion.  American Journal of Psychiatry, 141(12): 1621-1622, 1984.
  28. Liebowitz MR, Gorman JM, Fyer AJ, Levitt  M, Dillon D, Levy G, Appleby IL, Anderson S, Palij M, Davies SO and Klein DF: Lactate provocation of panic attacks: II. Biochemical and physiological findings.  Archives of General Psychiatry, 42:709-719, 1985.
  29. Liebowitz MR, Gorman JM, Fyer AJ, and Klein DF: Social phobia: Review of a neglected anxiety disorder.  Archives of General Psychiatry, 42:729-736, 1985.
  30. Gorman JM, Liebowitz MR, Fyer AJ, Campeas R, and Klein DF:  Treatment of social phobia with atenolol.  Journal of Clinical Psychopharmacology, 5(5):298-301, 1985.
  31. Gorman JM, Fyer AJ, Ross D, Cohen B, Martinez J, Liebowitz MR, and Klein DF:  Normalization of venous pH, CO, and bicarbonate levels after blockade of panic attacks.  Psychiatry Research, 14:57-65, 1985.
  32. Liebowitz MR, Karoum F, Quitkin FM, Davies SO, Schwartz D, Levitt M and Linnoila M:  Biochemical effects of  l-deprenyl in atypical depressives.  Biological Psychiatry, 20:558-565, 1985.
  33. Liebowitz MR, Fyer AJ, Gorman JM, Dillon D, Davies SO, Stein JM, Cohen BS and Klein DF:  Specificity of lactate infusions in social phobia vs panic disorders.  American Journal of Psychiatry, 142(8): 947-949, 1985.
  34. Gorman JM, Liebowitz MR, Fyer AJ, Levitt M, Baron M, Davies SO, and Klein DF:  Platelet monoamine oxidase activity in patients with panic disorder.  Biological Psychiatry, 20(8): 852-857, 1985. 
  35. Fyer AJ, Liebowitz MR, Gorman JM, Davies SO, and Klein DF:  Lactate vulnerability of remitted panic patients.  Psychiatry Research, 14:143-148, 1985.
  36. Gorman JM, Liebowitz MR, Fyer AJ, Dillon D, Davies SO, Stein J, and Klein DF:  Lactate infusions in obsessive-compulsive disorder.  American Journal of Psychiatry, 142(7): 864-866, 1985.
  37. Stewart JW, McGrath PJ, Liebowitz MR, Harrison W, Quitkin F, and Rabkin J: Treatment outcome validation of DSM-III depressive subtypes:  Clinical usefulness in outpatients with mild to moderate depression.  Archives of General Psychiatry, 42(12): 1148-1153, 1985.
  38. Liebowitz MR, Fyer AJ, Gorman JM, Campeas R, and Levin A:  Phenelzine in social phobia.  Journal of Clinical Psychopharmacology, 6(2): 93-98, 1986.
  39. Liebowitz MR, Fyer AJ, Gorman JM, Campeas R, Levin A, Davies SO, Goetz D, and Klein DF:  Alprazolam in the treatment of panic disorders.  Journal of Clinical Psychopharmacology, 6(1): 13-20, 1986.
  40. Liebowitz MR, Gorman JM, Fyer AJ, Dillon D, Levitt M, and Klein D: Possible mechanisms for lactate's induction of panic. American Journal of Psychiatry, 143:495-502, 1986.
  41. Gorman JM, Cohen BS, Liebowitz MR, Fyer AJ, Ross D, Davies SO, and Klein DF:  Blood gas changes and hypophosphatemia in lactate induced panic.  Archives of General Psychiatry, 43(11): 1067-1075, 1986.
  42. Fyer AJ, Liebowitz MR, Gorman JM, Campeas R, Levin A, Davies SO, Goetz D, and Klein DF:  Discontinuation of alprazolam treatment in panic patients.  American Journal of Psychiatry, 144(3): 303-308, 1987.
  43. Dillon DJ, Gorman JM, Liebowitz MR, Fyer AJ and Klein DF:  Measurement of lactate-induced panic and anxiety.  Psychiatry Research, 20:97-105, 1987.
  44. Levin AP, Doran AR, Liebowitz MR, Fyer AJ, Gorman JM, Klein DF and Paul SM:  Pituitary adrenocortical unresponsiveness in lactate-induced panic.  Psychiatry Research, 21(1): 23-32, 1987.
  45. Gorman JM, Liebowitz MR, Fyer AJ, Goetz D, Campeas RB, Fyer MR, Davies SO, and Klein DF:  An open trial of fluoxetine in the treatment of panic attacks.  Journal of Clinical Psychopharmacology, 7:329-332,1987.
  46. Gorman JM, Liebowitz MR, Dillon D, Fyer AJ, Cohen BS, and Klein DF:  Anti-panic drug effects during lactate infusion in lactate refractory panic patients.  Psychiatry Research, 21:205-212, 1987.
  47. Liebowitz MR, Fyer A, Gorman J, Campeas R, Levin A, Sandberg D, Hollander E and Papp LA:  Pharmacotherapy of social phobia.  Psychosomatics, 28(6):305-308, 1987.
  48. Fyer MN, Klein DF, Liebowitz MR, Fyer AJ, and Gorman JM:  5% C02/65% C02 challenge of panic disorder patients.  American Journal of Psychiatry, 144:1080-1082, 1987.
  49. McGrath PJ, Stewart JW, Markowitz J, Liebowitz MR, Quitkin FM, and Klein DF:  Lactate provocation of panic attacks in depressed outpatients.  Psychiatry Research, 25:41-47, 1987.
  50. Liebowitz MR, Gorman JM, Fyer AJ, Campeas R, Levin AP, Sandberg D, Hollander E, Papp L, and Goetz D:  Pharmacotherapy of social phobia:  A placebo controlled trial of phenelzine and atenolol.  Journal of Clinical Psychiatry, 49:252-257, 1988.
  51. Liebowitz MR, Quitkin FM, Stewart JW, McGrath PJ, Harrison WM, Markowitz JS, Rabkin JG, Tricamo E, Goetz DM, and Klein DF: Antidepressant specificity in atypical depression.  Archives of General Psychiatry, 45(2): 129-137, 1988.
  52. Gorman JM, Fyer MN, Goetz R, Askanazi J, Martinez J, Liebowitz MR, Fyer AJ, Kinney J, and Klein DF:  Ventilatory challenge studies of patients with panic disorder.  Archives of General Psychiatry, 45(1):31-39, 1988.
  53. Quitkin FM, Stewart JW, McGrath PJ, Liebowitz MR, Harrison WM, Tricamo E, Klein DF, Rabkin JG, Markowitz J, and Wager SG: Phenelzine vs imipramine in probable atypical depression:  Defining syndrome boundaries of selective MAOI responders.  American Journal of Psychiatry, 145(3):306-311, 1988.
  54. Gorman JM, Goetz RR, Fyer MR, King DL, Fyer AJ, Liebowitz MR, and Klein DF:  The mitral valve prolapse-panic disorder connection. Psychosomatic Medicine, 50(2):114-122, 1988.
  55. Fyer A, Liebowitz MR, Gorman JM, Campeas R, Levin A, Sandberg D,Hollander E, Goetz  D, and Klein DF:  Effect of clonidine on alprazolam discontinuation in panic patients:  A pilot study. Journal of Clinical Psychopharmacology, 8(4): 270-274, 1988.
  56. Versiani M, Mundim FD, Nardi AE, and Liebowitz MR:  Tranylcypromine in social phobia. Journal of Clinical Psychopharmacology, 8:279-283, 1988. 
  57. Gorman JM, Goetz RR, Uy J, Ross D, Martinez J, Fyer AJ, Liebowitz R, and Klein DF: Hyperventilation occurs during lactate-induced panic.  Journal of Anxiety Disorders, (2): 193-202, 1988.
  58. Hollander E, Fay M, Cohen B, Campeas R, Gorman JM, Sandberg D, and Liebowitz MR: Serotonergic and noradrenergic sensitivity in obsessive compulsive disorder:  Behavioral findings. American Journal of Psychiatry, 145(8)1015-1017, 1988.
  59. Papp LA, Liebowitz MR, Klein DF, Fyer AJ, and Gorman JM:  Epinephrine infusions in patients with social phobia. American Journal of Psychiatry, 145:733-736, 1988.
  60. Gorman JM, Liebowitz MR, Fyer AJ, and Stein J:  Neuroanatomical hypothesis of panic disorder.  American Journal of Psychiatry, 146:148-162, 1989.
  61. Gorman JM, Battista D, Goetz RR, Dillon DJ, Liebowitz MR, Fyer AJ, Kahn JP, Sandberg D, and Klein DF:  A comparison of sodium bicarbonate and sodium lactate infusion in the induction of panic attacks. Archives of General Psychiatry, 46(2): 145-150, 1989.
  62. Schneier FR, Martin LY, Liebowitz MR, Gorman JM, and Fyer AJ:  Alcohol abuse in social phobia.  Journal of Anxiety Disorders, 3:15-23, 1989.
  63. Hollander E, Liebowitz MR, Cohen B, Gorman J, Fyer AJ, and Klein DF:  Cortisol as a predictor of sodium lactate induced panic.  Archives of General Psychiatry, 46(2): 135-140, 1989.
  64. Hollander E, Liebowitz MR, Cohen B, Gorman J, Fyer AJ, and Klein DF: Prolactin and sodium lactate-induced panic.  Psychiatry Research. 28:181-191, 1989.
  65. Hollander E, Liebowitz MR, Winchel RW, Klumker A, and Klein DF: Treatment of body dysmorphic disorder with serotonin reuptake inhibitors.  American Journal of Psychiatry, 146:768-770, 1989.
  66. Papp L, Goetz R, Cole R, Klein DF, Jordan F, Liebowitz MR, Fyer AJ, Hollander E, and Gorman J: Hypersensitivity to carbon dioxide in panic disorder.  American Journal of Psychiatry, 146:779-781, 1989.
  67. Liebowitz MR, Hollander E, Schneier FR, Campeas R, Hatterer J, Papp L, Fairbanks J, Sandberg D, Davies S, and Stein M: Fluoxetine treatment of obsessive compulsive disorder:  An open clinical trial. Journal of Clinical Psychopharmacology, 9:423-427, 1989.
  68. Papp LA, Gorman JM, Fyer AJ, Liebowitz MR, Hollander E, and Klein DF:  Arterial blood gas findings in lactate induced panic. Psychiatry Research, 28:171-180; 1989.
  69. Hollander E, Schiffman E, Cohen B, Fyer AJ, Gorman JM, Papp L, and Liebowitz MR:  Signs of central nervous system dysfunction in OCD.  Archives of General Psychiatry, 47:27-32, 1990.
  70. Stewart J, McGrath P, Quitkin F, Harrison W, Markowitz J, Wager S, and Liebowitz MR:  Relevance of DSM-III depressive subtype and chronicity to antidepressant efficacy.  Archives of General Psychiatry, 46:1080-1087, 1990.
  71. Mannuzza S, Fyer AJ, Martin L, Gallops MS, Liebowitz MR, and Gorman JM: Reliability of anxiety assessment: I. Diagnosis agreement. Archives of General Psychiatry, 46:1093-1101, 1990.
  72. Fyer AJ, Mannuzza S, Martin L, Gallops M, Endicott J, Gorman JM, Liebowitz MR, and Klein DF: Reliability of anxiety assessment: II. Symptom agreement.  Archives of General Psychiatry, 46:1102-1110, 1990.
  73. Hatterer JA, Liebowitz MR, Gorman JM, Campeas RB, Schneier FR, Hollander E, and Papp LA: Pharmacotherapy of four men with paruresis. American Journal of Psychiatry, 147:109-111, 1990.
  74. 74.       Manuzza S, Fyer A, Liebowitz MR, and Klein DF:  Delineating the boundaries of social phobia: Its relationship to panic disorder and agoraphobia. Journal of Anxiety Disorders, 4:41-59, 1990.
  75. 75.       Swayne LC, Hamlin CL, and Liebowitz MR:  Striatal spect-IMP decrease in obsessive-compulsive disorder normalized by pharmacotherapy. Neuropsychiatry, Neuropsychology and Behavioral Neurology, 2:290-300, 1990.
  76. Towey J, Bruder G, Hollander E, Friedmen D, Erhan H, Liebowitz MR, and Sutton S:  Endogenous event-related potentials in obsessive-compulsive disorder.  Biological Psychiatry, 28:92-98, 1990.
  77. Hollander E, Liebowitz MR, DeCaria C, Fairbanks J, Fallon B, and Klein DF:  Treatment of depersonalization disorder with serotonin reuptake blockers. Journal of Clinical Psychopharmacology, 10:200-203, 1990.
  78. Schneier FR, Liebowitz MR, Davies S, Fairbanks J, Hollander E, Campeas R, and Klein DF:  Fluoxetine in panic disorder. Journal of Clinical Psychopharmacology, 10:119-121, 1990.
  79. Fyer AJ, Mannuzza S, Gallops MS, Martin LY, Aaronson C, Gorman JM, Liebowitz MR, and Klein DF: Familial transmission of simple phobias and fears:  A Preliminary Report.  Archives of General Psychiatry, 47:252-256, 1990.
  80. Gorman JM, Goetz, RR, Dillon D, Liebowitz MR, Fyer AJ, Davies S, and Klein DF: Sodium-d-lactate infusion of panic disorder patients.  Neuropsychopharmacology, 3:181-191, 1990. 
  81. Hollander E, DeCaria C, Schneier FR, Liebowitz MR, and Klein DF:  Fenfluramine augmentation of fluoxetine antiobsessional treatment.  Journal of Clinical Psychiatry, 51:119-123, 1990.
  82. Fallon BA, Liebowitz MR, Hollander E, Schneier FR, Campeas RB, Fairbanks J, Papp LA, Hatterer JA, and Sandberg D:  The pharmacotherapy of moral or religious scrupulosity.  Journal of Clinical Psychiatry, 51:517-521, 1990.
  83. Gorman JM, Papp LA, Martinez J, Goetz RR, Hollander E, Liebowitz MR, and Jordan F:  High-dose carbon dioxide challenge test in anxiety disorder patients.  Biological Psychiatry, 28:743-757, 1990.
  84. Liebowitz MR, Hollander E, Schneier F, Campeas R, Fallon B, Welkowitz L, Cloitre M, and Davies S: Anxiety and depression: Discrete diagnostic entities?  Journal of Clinical Psychopharmacology, 10(3S): 61S-66S, 1990.
  85. Schneier FR, Fyer AJ, Martin LY, Ross D, Mannuzza S, Liebowitz MR, Gorman JM, and Klein DF:  A comparison of phobic subtypes within panic disorder.  Journal of Anxiety Disorders, 5:65-75, 1991.
  86. Hollander E, Decaria C, Nitescu A, Gulley R, Cooper TB, Gorman JG, Liebowitz and MR: Noradrenergic function in obsessive compulsive disorder and normal controls: Neuroendocrine and behavioral responses to clonidine challenge.  Psychiatry Research, 37:161-177, 1991.
  87. Hollander E, Mullen L, DeCaria CM, Skodol A, Schneier FR, Liebowitz MR, and Klein DF:  Obsessive compulsive disorder, depression, and fluoxetine.  Journal of Clinical Psychiatry, 52(10): 418-422, 1991.
  88. Hollander E, Decaria C, Gully R, Nitescu A, Suckow RF, Gorman JM, Klein DF, and Liebowitz MR: Effects of chronic fluoxetine treatment on behavioral and neuroendocrine responses to m-chlorophenylpiperazine in obsessive-compulsive disorder.  Psychiatry Research, 36:1-17, 1991.
  89. Clomipramine Study Group:  Clomipramine in the treatment of patients with obsessive-compulsive disorder.  Archives of General Psychiatry, 48:730-738, 1991.
  90. Hollander E, DeCaria CM, Aronowitz B, Klein DF, and Liebowitz MR:  A pilot follow-up study of childhood soft-signs and the development of adult psychopathology.  Journal of Neuropsychiatry and Clinical Neurosciences, 3:186-189, 1991.
  91. Shear MK, Fyer AJ, Ball G, Josephson S, Fitzpatrick M, Gitlin B, Frances A, Gorman J, Liebowitz M, and Klein DF:  Vulnerability to sodium lactate in panic disorder patients given cognitive-behavioral therapy.  American Journal of Psychiatry, 148:795-797, 1991. 
  92. Cloitre M and Liebowitz MR:  Memory bias in panic disorder:  An investigation of the cognitive avoidance hypothesis. Cognitive Therapy and Research, 15(5): 371-386, 1991.
  93. Schneier FR, Spitzer RL, Gibbon M, Fyer A, and Liebowitz MR:  The relationship of social phobia subtypes and avoidant personality disorder.  Comprehensive Psychiatry, 32(6): 496-502, 1991.
  94. Fallon BA, Javitch JA, and Liebowitz MR:  Hypochondriasis: A variant of obsessive-compulsive disorder:  Overlaps in diagnosis and treatment.   Journal of Clinical Psychiatry, 52(11): 457-460, 1991.
  95. Welkowitz LA, Papp L, Cloitre M, Liebowitz MR, Martin L, and Gorman J:  Behavior therapy for panic disorder delivered by psychopharmacologically oriented clinicians. Journal of Nervous and Mental Disease, 79:472-476, 1991.
  96. Hollander E, DeCaria C, Nitescu A, Gully R, Suckow RF, Cooper TB, Gorman JM, Klein DF, and Liebowitz MR:  Serotonergic function in obsessive-compulsive disorder:  Behavioral and neuroendocrine responses to oral M-CPP and fenfluramine in patients and healthy volunteers.  Archives of General Psychiatry, 49(1): 21-28, 1992.
  97. Fallon BA, Campeas R, Schneier F, Hollander E, Hatterer J, Goetz D, Davies S, and Liebowitz MR:  An open trial of intravenous clomipramine in 5 treatment refractory OCD patients.  Journal of Neuropsychiatry and Clinical Neurosciences, 4(1): 70-75, 1992.
  98. Holt CS, Heimberg RG, Hope DA, and Liebowitz MR:  Situational domains of social phobia.  Journal Anxiety Disorders, 6(1): 63-77, 1992.
  99. Coplan J, Liebowitz MR, Gorman JM, Fyer AJ, Dillon D, Campeas R, Kahn J, Davies S, Martinez J, and Klein DF:  Effects of clonidine on lactate induced panic.  Biological Psychiatry, 31:135-146, 1992.
  100. Heimberg RG, Mueller GP,  Holt CS, Hope DA, and Liebowitz MR:  Assessment of anxiety in social  interaction and being observed by others: The social interactional anxiety scale and the social phobia scale. Behavior Therapy, 23:53-73, 1992.
  101. Liebowitz MR, Schneier FR, Campeas Raphael, Hollander E, Hatterer J, Fyer A, Gorman J, Papp L, Davies S, Gully R, and Klein DF:  Phenelzine vs. atenolol in social phobia: A placebo controlled comparison.  Archives of General Psychiatry, 49:290-300, 1992.
  102. Schneier FR, Johnson J, Hornig CD, Liebowitz MR, and Weissman MM:  Social phobia: Comorbidity and morbidity in an epidemiological sample. Archives of General Psychiatry, 49:282-298, 1992.
  103. Cloitre M, Heimberg RG, Liebowitz MR, and Gitow A: Perceptions of control in panic and social phobia.  Cognitive Therapy and Research, 16(5): 569-577, 1992.
  104. Stein DJ, Hollander E, Antony DT, Becker J, Schneier F, Fallon B, Liebowitz MR, and Klein DF:  Sexual compulsions, obsessive compulsive disorder, and serotonergic medications.  Journal Clinical Psychiatry, 53(8): 267-271, 1992.
  105. Versiani M, Nardi E, and Liebowitz MR:  Phenelzine vs moclobemide in social phobia:  A placebo controlled trial.  British Journal of Psychiatry, 161:353-360, 1992.
  106. Cloitre M, Heimberg RG, Holt C, and Liebowitz MR:  Reaction time to threat stimuli in panic disorder and social phobia. Behaviour Research and Therapy, 30:609-617, 1992.
  107. Stein D, Hollander E, and Liebowitz MR:  Treatment of obsessive-compulsive disorder with alprazolam and clomipramine. Human Psychopharmacology, 7:387-395, 1992.
  108. Hollander E, Neville D, Frenkel M, Josephson S, Liebowitz MR, and Klein DF:  Body dysmorphic disorder: Diagnostic issues and related disorders.  Psychosomatics, 33(2): 156-165, 1992.
  109. Carrasco JL, Hollander E, Schneier FR, and Liebowitz MR:  Treatment outcome of obsessive-compulsive disorder with comorbid social phobia.  Journal of Clinical Psychopharmacology, 53:387-391, 1992.
  110. Fallon BA, Nields JA, Burrascano JJ, Liegner K, DelBene D, and Liebowitz MR: The neuropsychiatric manifestations of Lyme borreliosis.  Psychiatric Quarterly, 63:95-117, 1992.
  111. Fallon BA, Rasmussen SA, and Liebowitz MR:  Hypochondriasis:  Treatment strategies. Psychiatric Annals, 23(7): 374-381, 1993.
  112. Schneier FR, Carrasco J, Hollander E, Campeas R, Fallon B, Saoud JB, Feerick J, and Liebowitz MR:  Alpidem in panic disorder. Journal of Clinical Psychopharmacology, 13:150-153, 1993.
  113. Stein DJ, Hollander E, and Liebowitz MR:  Neurobiology of impulsivity and impulse-control disorders.  Journal Neuropsychiatry and Clinical Neurosciences, 5:9-17, 1993.
  114. Fyer AJ, Mannuzza S, Chapman T, Liebowitz MR, and Klein DF:  A direct interview family study of social phobia.  Archives of General Psychiatry, 50:286-293, 1993.
  115. Hurowitz GI and Liebowitz MR:  Antidepressant-induced rapid cycling: Six case reports. Journal of Clinical Psychopharmacology, 13(1): 52-56, 1993.
  116. Maddock RJ, Carter CS, Blacker KH, Beitman BD, Krishnan KR, Jefferson JW, Lewis PC, and Liebowitz MR:  Relationship of past depressive episodes to symptom severity and treatment response in panic disorder with agoraphobia.  Journal of Clinical Psychiatry, 54(3): 88-94, 1993.
  117. Hollander E, DeCaria CM, Saoud JB, Klein DF, and Liebowitz MR:  A pilot study of biological predictors of treatment outcome in obsessive-compulsive disorder.  Biological Psychiatry, 33:747-749, 1993.
  118. Goetz RR, Gully R, Dillon DJ, Kahn J, Liebowitz MR, Fyer AJ, Klein DF, and Gorman JM: Panic attacks during laboratory placebo procedures:  Physiology and symptomatology. Archives of General Psychiatry, 50:280-285, 1993.
  119. Schneier FR, Saoud JB, Campeas R, Fallon BA, Hollander E, Coplan J., and Liebowitz MR: Buspirone in social phobia.  Journal of Clinical Psychopharmacology, 13(4) 251-256, 1993.
  120. Levin AP, Saoud J, Strauman T, Gorman J, Fyer AJ, Crawford R, and Liebowitz MR:  Responses of "generalized" and "discrete" social phobics during public speaking. Journal of Anxiety Disorders, 7:207-221, 1993.
  121. Fallon BA, Nields JA, Parsons B, Liebowitz MR, and Klein DF:  Psychiatric manifestations of lyme borreliosis.  Journal of Clinical Psychiatry, 54(7): 263-268, 1993.
  122. Heimberg RG, Holt CS, Schneier FR, Spitzer RL, and Liebowitz MR:  The issue of subtypes in the diagnosis of social phobia.  Journal of Anxiety Disorders, 7:249-269, 1993.
  123. Hollander E, Cohen LJ, DeCaria C, Saoud JB, Stein DJ, Cooper TB, Islam NN, Liebowitz MR, and Klein DF:  Timing of Neuroendocrine responses and effect of m-CPP and fenfluramine plasma levels in OCD.  Biological Psychiatry, 34:407-413, 1993.
  124. Gorman JM, Papp LA, Coplan J, Martinez J, Liebowitz MR, and Klein DF.  The effect of acetazolamide on ventilation in panic disorder patients.  American Journal of Psychiatry, 150(10): 1480-1484, 1993.
  125. Fallon BA, Liebowitz MR, Salmán E, Schneier FR, Jusino C, Hollander E, and Klein DF: Fluoxetine for hypochondriacal patients without major depression.  Journal of Clinical Psychopharmacology, 13(6) 438-443, 1993.
  126. Hollander E, Stein DJ, Saoud JB, DeCaria CM, Cooper TB, Trungold S, Stanley M, and Liebowitz MR:  Effects of fenfluramine on plasma homovanillic acid in healthy controls and patients with obsessive-compulsive disorder.  Journal of Clinical Psychiatry, 4(2): 185-188, 1993.
  127. Prichep LS, Mas F, Hollander E, Liebowitz M, John ER, Almas M, DeCaria CM, and Levine R:  Quantitative electroencephalographic (QEEG) subtyping of obsessive compulsive disorder. Psychiatry Research: Neuroimaging, 50:25-32, 1993.
  128. Stein DJ, Hollander E, Chan S, DeCaria CM, Hilal S, Liebowitz MR, and Klein DF: Computed tomography and neurological soft signs in obsessive-compulsive disorder. Psychiatry Research: Neuroimaging, 50:143-150, 1993.
  129. Oberlander E, Liebowitz MR, and Schneier FR:  Physical disability and social phobia.  Journal of Clinical Psychopharmacology, 14:136-143, 1994.
  130. Towey J, Tenke C, Bruder GE, Leite P, Friedman D, Liebowitz MR, and Hollander E: Brain event-related potential correlates of over focused attention in obsessive-compulsive disorder (OCD).  Psychophysiology, 31:535-543, 1994.
  131. Zinbarg RE, Barlow DH, Liebowitz M, Street L, Broadhead E, Katon W, Roy-Byrne PR, Levine J, Teherani M, Richards J, Brantley P, and Kraemer H:  The DSM-IV field trial for mixed anxiety depression.  American Journal of Psychiatry, 151(8): 1153-1162, 1994.
  132. Schneier FR, Heckelman LR, Garfinkel R, Campeas R, Fallon B, Gitow A, Street L, DelBene D, and Liebowitz, MR:  Functional impairment in social phobia.  Journal of Clinical Psychiatry, 55:322-331, 1994.
  133. Liebowitz MR, Salmán E, Jusino CM, Garfinkel R, Street L, Cárdenas DL, Silvestre J, Fyer A, Carrasco JL, Davies S, Guarnaccia P, and Klein DF:  Ataque de nervios and panic disorder.  American Journal of Psychiatry, 151(6): 871-875, 1994.
  134. Lipsitz JD, Martin LY, Mannuzza S, Chapman TF, Liebowitz MR, Klein DF, and Fyer AJ: Childhood separation anxiety disorder in patients with adult anxiety disorders.  American Journal of Psychiatry, 151(6): 927-929, 1994.
  135. Aronowitz B, Liebowitz MR, Fazzini E, Durlach-Misteli C, Frenkel M, Mosovich S, Garfinkel R, Saoud J, DelBene D, Cohen L, Jaeger A, and Rubin AL:  Neuropsychiatric and neuropsychological findings in conduct disorder and attention-deficit hyperactivity disorder. Journal of Neuropsychiatry and Clinical Neurosciences, 6:245-249, 1994.
  136. Davidson JRT, Beitman B, Greist JH, Maddock RJ, Lewis CP, Sheridan AQ, Carter C, Krishnan KP, Liebowitz MR, and Haack DG: Adinazolam SR treatment of panic disorder:  A double-blind study.  Journal of Clinical Psychopharmacology, 14(4): 255-263, 1994.
  137. Brown TA, Barlow DH, and Liebowitz MR:  The empirical basis of generalized anxiety disorder.  American Journal of Psychiatry, 151:1272-1280, 1994.
  138. Roy-Byrne P, Katon W, Broadhead WE, Lepine JP, Richards J, Brantley PJ, Russo J, Zinbarg R, Barlow D, and Liebowitz MR: Subsyndromal ("mixed") anxiety-depression in primary care.  Journal of General Internal Medicine, 9:507-512, 1994.
  139. Aronowitz B, Hollander E, DeCaria C, Cohen L, Saoud J, Stein D, Liebowitz MR, and Rosen W: Neuropsychology of obsessive compulsive disorder.  Neuropsychiatry, Neuropsychology, and Behavioral Neurology, 7(2): 81-86, 1994.
  140. Coplan JD, Papp LA, Martinez J, Pine D, Rosenblum LA, Cooper T, Liebowitz MR, and Gorman JM: Persistence of blunted human growth hormone response to clonidine in fluoxetine-treated patients with panic disorder.  American Journal of Psychiatry, 152(4): 619-622, 1995.
  141. Greist JH, Chouinard G, Duboff E, Halaris A, Kim SW, Koran L, Liebowitz MR, Lydiard RB, Rasmussen S, White K, and Sikes C: Double-blind parallel comparison of three dosages of sertraline and placebo in outpatients with obsessive-compulsive disorder. Archives of General Psychiatry, 52:289-295, 1995.
  142. Manuzza S, Schneier FR, Chapman TF, Liebowitz MR, Klein DF, and Fyer AJ: Generalized social phobia: Reliability and validity. Archives of General Psychiatry, 52:230-237, 1995.
  143. Carter CS, Fawcett J, Hertzman M, Papp LA, Jones W, Patterson WM, Swinson RP, Weise CC, Maddock RJ, Denahan AQ, and Liebowitz M: Adinazolam-SR in panic disorder with agoraphobia: Relationship of daily dose to efficacy.  Journal of Clinical Psychiatry, 56(5): 202-210, 1995.
  144. Cloitre M, Cancienne J, Heimberg RG, Holt CS, and Liebowitz M: Memory bias does not generalize cross anxiety disorders. Behaviour, Research, and Therapy, 33(3): 305-308, 1995.
  145. Liebowitz MR, Coplan JD, Martinez J, Fyer AJ, Dillon DJ, Campeas RB, Davies SO, Gorman JM, and Klein DF: Effects of intravenous diazepam pretreatment on lactate-induced panic.  Psychiatry Research, 58:127-138, 1995.
  146. Reschke AH, Mannuzza S, Chapman TF, Lipsitz JD, Liebowitz MR, Gorman JM, Klein DF, and Fyer AJ: Sodium lactate response and familial risk for panic disorder.  American Journal of Psychiatry, 152(2): 277-279, 1995.
  147. Cohen LJ, Hollander E, DeCaria CM, Stein DJ, Simeon D, Liebowitz MR, and Aronowitz B: Specificity of neuropsychological impairment in obsessive compulsive disorder: A comparison with social phobics and normal controls subjects.  Journal of Neuropsychiatry and Clinical Neurosciences, 8:82-85, 1996.
  148. Hollander E, Weiller F, Cohen L, Kwon JH, Decaria CM, Liebowitz MR, and Stein DJ: Neurological soft signs in social phobia. Neuropsychiatry, Neuropsychology and Behavioral Neurology, 9(3): 182-185, 1996.
  149. Schneier FR, Garfinkel R, Kennedy B, Campeas R, Fallon BA, Marshall RD, O'Donnell L, Hogan T, and Liebowitz MR: Ondansetron in the treatment of panic disorder.  Anxiety, 2(4): 199-202, 1996.
  150. Clarvit SR, Schneier FR, and Liebowitz MR: The offensive subtype of Taijin-Kyofu-Sho in New York City: The phenomenology and treatment of a social anxiety disorder.  Journal of Clinical Psychiatry, 57:523-527,1996.
  151. Schneier FR, Goetz D, Wexler KB, and Liebowitz MR:  Social phobia symptoms in adults who stutter. American Journal of Psychiatry, 153:131, 1996.
  152. Schneier FR, Juster H, Heimberg R, Liebowitz MR: Diagnosis and treatment of social phobia.  Journal of Practical and Behavioral Health, 26:210-216, 1996.
  153. Liebowitz MR, Heimberg RG: Issues in the design of trials for the evaluation of psycho-pharmacological treatments for social phobia. International Clinical Psychopharmacology, 11(3): 49-52, 1996.
  154. Heimberg R, Liebowitz MR: Issues in the design of trials for the evaluation of psychosocial treatment for social phobia.  International Clinical Psychopharmacology, 11(3): 55-64, 1996.
  155. Noyes R, Moroz G, Davidson J, Liebowitz MR, Davidson A, Siegel J, Bell J, Cain J, Curlik SM, Kent T, Lydiard B, Mallinger A, Pollack M, Rapport M, Rasmussen S, Reimherr F, Schweizer, and Uhlenhuth EH: Moclobemide in social phobia: a controlled dose-response trial.  Journal of Clinical Psychopharmacology, 17(4): 247-254, 1997.
  156. Papp L, Schneier, Fyer AJ, Liebowitz MR, Gorman J, Coplan JD, Saoud J, Campeas R, Fallon B, Jusino C, and Klein DF: Clomipramine treatment of panic disorder: Pro=s and Con=s. Journal of Clinical Psychiatry, 58(10): 423-425, 1997.
  157. Fallon BA, Bird H, Hoven, Cameron D, Liebowitz MR, and Shaffer D: Psychiatric aspects of lyme disease in children and adolescents: A community epidemiologic study in Westchester, New York. Journal of Spirochetal plus Tick-Born Diseases, 1:98-100, 1997.
  158. Rasmussen S, Hackett E, DuBoff E, Greist J, Halaris A, Koran L, Liebowitz MR, Lydiard RB, McElroy S, Mendels J, and O'Connor K: A two-year study of sertraline in the treatment of obsessive compulsive disorder.  Int Clin Psychopharmacology, 12(6): 309-316, 1997.
  159. Street L, Salmán E, Garfinkel R, Silvestre J, Carrasco J, Cárdenas D, Zinbarg RE, Barlow DH, and Liebowitz MR:  Discriminating between generalized anxiety disorder and anxiety disorder, not otherwise specified:  Is it only a matter of worry?  Depression and Anxiety, 1997, 5:1 1-6.
  160. Liebowitz MR: Panic disorder as a chronic illness.  Journal of Clinical Psychiatry, 58(13): 5-8, 1997.
  161. Salmán E, Liebowitz MR, Guarnaccia P, Jusino CM, Garfinkel R, Street L, Cárdenas DL, Silvestre J, Fyer A, Carrasco JL, Davies S, Klein DF: Subtypes of ataques de nervios:  The influence of coexisting psychiatric diagnosis.  Culture, Medicine, and Psychiatry, 22(2): 231-244, 1998.
  162. Schneier FR, Goetz D, Campeas R, Marshall R, Fallon B, Liebowitz MR: A placebo-controlled trial of moclobemide in social phobia. British Journal of Psychiatry, 172:70-77, 1998.
  163. Simpson HB, Schneier FR, Campeas R, Marshall RD, Fallon B, Davies S, Klein DF, Liebowitz MR: Imipramine in the treatment of social phobia.  Journal of Clinical Psychopharmacology, 18(2): 132-135, 1998.
  164. Simpson HB, Schneier FR, Marshall RD, Campeas RB, Vermes D, Silvestre J, Davies S, Liebowitz MR:  Low dose selegiline (L-Deprenyl) in social phobia.  Depression and Anxiety, 7(3):126-129,1998.
  165. Turk CL, Heimberg RH, Orsillo S, Holt CS, Gitow A, Street LL, Liebowitz: An investigation gender differences in social phobia. Journal of Anxiety Disorders, 12(3): 209-223, 1998.
  166. Stein MB, Liebowitz MR, Lydiard RB, Pitts CD, Bushnell W, Gergel I: Paroxetine treatment of generalized social phobia (social anxiety disorder): A randomized, double-blind, placebo-controlled study.  Journal of the American Medical Association (JAMA), 280:708-713, 1998.
  167. Marshall RD, Schneier FR, Charles BG, Knight CBG, Abbate LA, Fallon B, Goetz D, Campeas R, Liebowitz MR: Open trial of paroxetine in patients with non-combat-related, chronic PTSD.  Journal of Clinical Psychopharmacology, 18:10-18, 1998.
  168. Liebowitz MR: Anxiety disorders and obsessive-compulsive disorder. Neuropsychobiology, 37(2) 69-71, 1998.
  169. Hollander E, Kwon J, Weiller F, Cohen L, Stein DJ, DeCaria C, Liebowitz M, Simeon D. Serotonergic function in social phobia: comparison to normal control and obsessive-compulsive disorder subjects.  Psychiatry Research, 79(3):213-217, 1998.
  170. Fallon BA, Liebowitz MR, Campeas R, Schneier FR, Marshall RD, Davies S, Goetz D, and Klein DF: Intravenous clomipramine for obsessive compulsive disorder refractory to oral clomipramine: A placebo controlled study.  Archives of General Psychiatry, 55(10):918-924, 1998.
  171. Heimberg RG, Liebowitz MR, Hope DA, Schneier FR, Holt CS, Welkowitz LA, Juster HR, Campeas R, Bruch MA, Cloitre M, Fallon B, Klein DF:  Cognitive-behavioral group therapy versus phenelzine in social phobia: 12-week outcome.  Archives of General Psychiatry, 55(12): 1133-1141, 1998.
  172. Heimberg RH, Horner KJ, Juster HR, Safren SA, Schneier FR, Liebowitz MR: Psychometric properties of the Liebowitz social anxiety scale.  Psychological Medicine, 29(1):199-212, 1999.
  173. Safren SA, Heimberg RH, Horner KJ, Juster HR, Schneier FR, Liebowitz MR: Factor structure of social fears: The Liebowitz social anxiety scale.  Journal of Anxiety Disorders, 13(3):253-270, 1999.
  174. Simpson HB, Gorfinkle KS, Liebowitz MR: Cognitive-behavioral therapy as an adjunct to serotonin reuptake inhibitors in obsessive-compulsive disorder: an open trial.  Journal of Clinical Psychiatry, 60(9):584-590, 1999.
  175. Marshall RD, Spitzer R, Liebowitz MR: Review and critique of the new DSM-IV Diagnosis of Acute Stress Disorder. The American Journal of Psychiatry, 156:1677-1685, 1999.
  176. Liebowitz MR, Heimberg RG, Schneier FR, Hope DA, Davies S, Holt CS, Goetz D, Juster HR, Shu-Hsing L, Bruch MA, Marshall RD, Klein DF: Cognitive-Behavioral Group Therapy Versus Phenelzine in Social Phobia: Long Term Outcome.  Depression and Anxiety, 10:89-98, 1999.
  177. Wittchen HU, Fuetsch M, Sonntag H, Muller N, Liebowitz M.  Disability and quality of life in pure and comorbid social phobia findings from a controlled study.  European Psychiatry, 14(3):118-131, 1999.
  178. Hart TA, Turk CL, Heimberg RG, Liebowitz MR. Relation of marital status to social phobia severity. Depression and Anxiety, 10(1):28-32, 1999.
  179. Fallon BA, Tager F, Fein L, Liegner K, Keilp J, Weiss N, Liebowitz MR: Repeated antibiotic treatment in chronic Lyme disease. Journal of Spirochetal and Tick-borne Diseases, 6:94-102, 1999. 
  180. Marshall RD, Schneier FR, Shu-Hsing L, Simpson HB, Vermes D, Liebowitz MR: Childhood Trauma and Dissociative Symptoms in Panic Disorder.  American Journal of Psychiatry, 157:451-453, 2000.
  181. Schneier FR, Liebowitz MR, Abi-Dargham A, Zea-Ponce Y, Shu-Hsing L, Laruelle M: Low Dopamine D2 Receptor binding potential in Social Phobia.  American Journal of Psychiatry, 157:457-459, 2000.
  182. Liebowitz MR, Heimberg RG, Fresco DM, Travers J, Stein MB:  Social phobia or social anxiety disorder: what's in a name? Archives of General Psychiatry, 57(2):191-192, 2000.
  183. Wittchen HU, Fuetsch M, Sonntag H, Muller N, Liebowitz M:  Disability and quality of life in pure and comorbid social phobia: Findings from a controlled study.  European Psychiatry, 15(1):46-58, 2000.
  184. Schechter DS, Marshall R, Salmán E, Goetz D, Davies S, Liebowitz MR:  Ataque de nervios and history of childhood trauma. Journal of Traumatic Stress, 13(3):529-534, 2000.
  185. Simpson HB, Tenke CE, Towey JB, Liebowitz MR, Bruder GE:  Symptom provocation alters behavioral ratings and brain electrical activity in obsessive-compulsive disorder: A preliminary study.  Psychiatry Research, 95(2):149-155, 2000.
  186. Eng W, Heimberg RG, Coles ME, Schneier FR, Liebowitz MR:  An empirical approach to subtype identification in individuals with social phobia.  Psychological Medicine, 30(6):1345-1357, 2000.
  187. Blanco C, Nissenson K, Liebowitz MR:  Social anxiety disorder: Recent findings in the areas of epidemiology, etiology, and treatment. Current Psychiatry Reports, 3(4):273-280, 2001.
  188. Sánchez-LaCay JA, Lewis-Fernández R, Goetz D, Blanco C, Salmán E, Davies S, Liebowitz MR:  An open trial of Nefazodone among Hispanics with Major Depression: Efficacy, Tolerability, and Adherence issues.  Depression and Anxiety, 13:118-124, 2001.
  189. Fresco DM, Coles ME, Heimberg RG, Liebowitz MR, Hami S, Stein MB, Goetz D:  The Liebowitz Social Anxiety Scale: A comparison of the psychometric properties of self-report and clinician- administered formats. Psychological Medicine, 6:1025-1035, 2001.
  190. Eng W, Heimberg RG, Hart TA,Schneier FR, Liebowitz MR:  Attachments in individuals with social anxiety disorders: The relationship among adult attachment styles, social anxiety and depression. Emotions, 1:365-380, 2001.
  191. Mathew SJ, Coplan JD, Perko KA, Goetz RR, de la Nuez M, Hollander E, Liebowitz MR, Fallon BA:  Neuroendocrine predictors of response to intravenous clomipramine therapy for refractory obsessive-compulsive disorder. Depression and Anxiety, 14(4):199-208, 2001.
  192. Tager FA, Fallon BA, Keilp J, Rissenberg M, Jones CR, Liebowitz MR:  A controlled study of cognitive deficits in children with chronic Lyme disease.  Journal Neuropsychiatry Clinical Neuroscience, 13(4): 500-507, 2001.
  193. Stein DJ, Westenberg HG, Liebowitz MR:  Social anxiety disorder and generalized anxiety disorder: Serotonergic and dopaminergic neurocircuitry.  Journal of Clinical Psychiatry, 63 (Supplement 6):12-19, 2002.
  194. Mennin DS, Fresco DM, Heimberg RG, Schneier FR, Davies SO, Liebowitz MR:  Screening for social anxiety disorder in the clinical setting: Using the Liebowitz Social Anxiety Scale.  Journal of Anxiety Disorders, 16:661-673, 2002.
  195. Liebowitz MR, Stein MB, Tancer M, Carpenter D, Oakes R, Pitts CD:  A randomized, double-blinded, fixed-dose comparison of paroxetine and placebo in the treatment of generalized social anxiety disorder. Journal of Clinical Psychiatry, 63(1):66-74, 2002.
  196. Blanco C, Antia SX, Liebowitz MR:  Pharmacotherapy of social anxiety disorder.  Biological Psychiatry, 51(1):109-120, 2002.
  197. Lewis-Fernández R, Guarnaccia PJ, Martinez IE, Salmán E, Schmidt A, Liebowitz MR:  Comparative  phenomenology of ataques de nervios, panic attacks, and panic disorder.  Culture, Medicine, and Psychiatry, 26(2):199-223, 2002.
  198. Marshall RD, Blanco C, Printz D, Michael Liebowitz MR, Klein DF, Coplan J:  A Pilot Study of Noradrenergic and HPA axis Functioning in PTSD vs. Panic Disorder. Psychiatry Research, 110(3): 219-230, 2002.
  199. Harb GC, Heimberg RG, Fresco DM, Schneier FR, Liebowitz MR:  The psychometric properties of the Interpersonal Sensitivity Measure in social anxiety disorder.  Behavioral Research & Therapy, 40(8): 961B979, 2002.
  200. Schneier FR, Blanco C, Anita SX, Liebowitz MR:  The social anxiety spectrum. Psychiatric Clinics of North America, 25(4):757-774, 2002.
  201. Liebowitz MR, Turner SM, Piacentini J, Beidel DC, Clarvit SR, Davies SO, Graae F, Jaffer M, Lin S, Sallee FR, Schmidt AB, Simpson HB:  Fluoxetine in children and adolescents with OCD: A placebo - controlled trial.  Journal of the American Academy of Child and Adolescent Psychiatry, 41:12, 2002.
  202. Feinstein SB, Fallon BA, Petkova E, Lieowitz MR:  Item-by-item factor analysis of the Yale-Brown Obsessive Compulsive Scale Symptom Checklist.  Journal of Neuropsychiatry and Clinical Neuroscience, 15(2):187-193, 2003.
  203. Zaider TI, Heimberg RG, Fresco DM, Schneier FR, Liebowitz MR:  Evaluations of the global impression scale among individuals with social anxiety disorder.  Psychological Medicine, 33(4): 611-622, 2003.
  204. Schneier FR, Blanco C, Campeas R, Lewis-Fernández R, Lin S, Marshall R, Schmidt A, Sánchez-LaCay JA, Simpson HB, Liebowitz MR: Citalopram treatment of Social Anxiety Disorder with comorbid major depression.  Depression and Anxiety, 17(4):191-196, 2003.
  205. Fallon BA, Qureshi AI, Schneier FR, Sánchez-LaCay A, Vermes D, Feinstein R, Connelly J, Liebowitz MR:  An open trial of fluvoxamine for hypochondriasis.  Psychosomatics, 44(4):298-303, 2003.
  206. Liebowitz MR, DeMartinis NA, Weihs K, Londborg PD, Smith WT, Chung H, Fayyad R, Clary CN:  Efficacy of sertraline in severe generalized social anxiety disorder: Results of a double-blind placebo-controlled study.  Journal of Clinical Psychiatry, 64(7):785-792, 2003.
  207. Hambrick JP, Turk CL, Heimberg RD, Schneier FR, Liebowitz MR:  The experience of disability and quality of life in social anxiety disorder. Depression and Anxiety, 18(1):46-50, 2003.
  208. Masia-Warner C, Storch EA, Pincus DB, Klein RG, Heimberg RG, Liebowitz MR:  Liebowitz Social Anxiety Scale for children and adolescents: An initial psychometric investigation. Journal of the American Academy of Child and Adolescent Psychiatry, 42(9):1076-84, 2003.
  209. Shaywitz JE, Liebowitz MR:  Antiepileptic treatment of anxiety disorders.  Primary Psychiatry, 10(10):51-56, 2003.
  210. Blanco C, Raza MS, Schneier FR, Liebowitz MR:  The evidence-based pharmacological treatment of social anxiety disorder. International Journal of Neuropsychopharmacology, 6(4):427-442, 2003.
  211. Simpson HB, Lombardo I, Slifstein M, Huang HY, Hwang DR, Abi-Dargham A, Liebowitz MR, Laurelle M:  Serotonin transporters in obsessive-compulsive disorder: A positron emission tomography study with [(11)C]McN 5652. Biological Psychiatry, 54(12):1414-1421, 2003.
  212.  Hambrick JP, Turk CL, Heimberg RG, Schneier FR, Liebowitz MR:  Psychometric properties of disability measures among patients with social anxiety disorder. Journal of Anxiety Disorders, 18: 825-839, 2004.
  213. Simpson HB, Liebowitz MR, Foa EB, Koak MJ, Schmidt AB, Rowan V, Petkova E, Kjernisted K, Huppert JD, Franklin ME, Davies SO, Campeas R: Post-treatment effects of exposure therapy and clomipramine in OCD.  Depression and Anxiety 19: 225-233, 2004.
  214. Westenberg HG, Liebowitz MR: Overview of panic and social anxiety disorders.  Journal of Clinical Psychiatry 65(14):22, 2004.
  215. Schechter DS, Zeabah CH JR, Myers MM, Brunelli SA, Liebowitz MR, Marshall RD, Coates SW, Trabka KA, Baca P, Hofer MA: Psychobiological dysregulation in violence-exposed mother: Salivary cortisol of mothers with very young children pre-and post-separation     stress.  Bulletin Menninger Clinic 68(4): 319-336, 2004.
  216. Blanco C, Goodwin RD, Liebowitz MR, Schmidt AB, Lewis-Fernandez R, Olfson M:  Use of psychotropic medication for patients with office visits who receive a diagnosis of panic disorder.  Medical Care 42(12):1242-1246, 2004.
  217. Liebowitz MR: Social anxiety disorder: Importance and awareness.  Primary Care Psychiatry 9(3):97-104, 2004.
  218. Foa EB, Liebowitz MR, Kozak MJ, Davies SO, Campeas R, Frankklin ME, Huppert JD, Kjernisted K, Rowan V, Schmidt AB, Simpson HB, Tu X:  Randomized, placebo-controlled trial of exposure and ritual prevention, clomipramine and their combination in the treatment of obsessive-compulsive disorder.  American Journal of Psychiatry 162(1):151-161, 2005.
  219. Liebowitz MR, Gelenberg AJ, Munjack D:  Venlafaxine extended-release vs. placebo and paroxetine in social anxiety disorder. Archives of General Psychiatry 62(2):190-198, 2005.
  220. Liebowitz MR, Mangano RM, Bradwejn J, Asnis G:  A randomized controlled trial of venlafaxine extended-release in generalized social anxiety disorder.  Journal of Clinical Psychiatry 66(2):238-247, 2005.
  221. Liebowitz MR, Ninan PT, Schneier FR, Blanco C.:  Integrating neurobiology and psychopathology into evidence-based treatment of social anxiety disorder.  CNS Spectrums 10(10) Supplement 13: 1-11; Discussion 12-3; Quiz 14-5, 2005.
  222. Schechter DS, Coots T, Zeanah CH, Davies M, Coates SW, Trabka KA, Marshall RD, Liebowitz MR, Myers MM:  Maternal mental representations of the child in an inner-city clinical sample: violence-related posttraumatic stress and reflective functioning. Attachment & Human Development (3):313-31, 2005.
  223. Simpson HB, Franklin ME, Cheng J, Foa EB, Liebowitz MR:  Standard criteria for relapse are needed in obsessive-compulsive disorder.  Depression and Anxiety 21(1):1-8, 2005.
  224. Weeks JW, Heimberg RG, Fresco DM, Hart TA, Turk CL, Schnieier FR, Liebowitz MR:  Empirical validation and psychometric evaluation of the Brief Fear of Negative Evaluation Scale in patients with social anxiety disorder.  Psychological Assessment 17: 179-190, 2005.
  225. Belser K, Mckee MB, Liebowitz MR: Social anxiety disorder: Current perspectives on diagnosis and treatment. Primary Psychiatry 12(11): 40-53, 2005. 
  226. Hughes AA, Heimberg RG, Coles ME, Gibb BE, Liebowitz MR, Schneier FR:  Relations of the factors of  the tripartite model of anxiety and depression to types of social anxiety.  Behavioral Research and Therapy 44: 1629-41, 2006.
  227. Simpson HB, Rosen W, Huppert JD, Lin SH, Foa EB, Liebowitz MR:  Are there reliable neuropsychological deficits in obsessive-compulsive disorder? Journal of Psychiatric Research 40: 247-57, 2006.
  228. Rodebaugh TL, Woods CM, Heimberg RG, Liebowitz MR Schneier FR:  The factor structure and screening utility of the Social Interaction Anxiety Scale. Psychological Assessment 18: 231-7, 2006.
  229. Schulz LT, Heimberg RT, Rodebaugh TL, Schneier FR, Liebowitz MR, Telch MJ :  The Appraisal of Social Concerns Scale: Psychometric validation with a clinical sample of patients with social anxiety disorder. Behavior Therapy 37: 392-405, 2006.
  230. Simpson HB, Huppert JD, Petkova E, Foa EB, Liebowitz MR: Response versus remission in obsessive compulsive disorder. Journal of Clinical Psychiatry 67: 269-76, 2006.
  231. Schechter DS, Myers MM, Brunelli SA, Coates SW, Zeanah CH, Davies M, Grienenberger JF, Marshall RD, McCaw JE, Trabka KA, Liebowitz MR: Traumatized mothers can change their minds about their toddlers: Understanding how a novel use of videofeedback supports positive change of maternal attributions. Infant Mental Health Journal, 27(5): 429-48, 2006.
  232. Huppert JD, Walther MR, Hajcak G, Yadin E, Foa EB, Simpson HB, Liebowitz MR: The OCI-R: Validation of subscales in a clinical sample. Journal of Anxiety Disorders 21 (3): 394-406, 2007. 
  233. Liebowitz MR, Yeung PP, Entsuah R: A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in adult outpatients with major depressive disorder.  Journal of Clinical Psychiatry 68 (11): 1663-72, 2007.
  234. Marshall RD, Lewis-Fernandez R, Blanco C, Simpson HB, Lin H, Vermes D, Garcia W,  Schneier FR, Neria Y, Sanchez-LaCay A, Liebowitz MR: A controlled trial of paroxetine for chronic PTSD, dissociation and interpersonal problems in mostly minority adults. Depression and Anxiety 24 (2): 77-84, 2007.
  235. Hartford J, Kornstein S, Liebowitz MR, Pigott T, Russell J, Detke M, Walker D, Ball S, Dunayevich E, Dinkel J, Erickson J: Duloxetine as an SNRI treatment for generalized anxiety disorder: Results from a placebo and active controlled trial. International Clinical Psychopharmacology 22 (3): 167-74, 2007.
  236. Lipsitz JD, Gur M, Vermes D, Petkova E, Cheng J, Miller N, Laino J, Liebowitz MR, Fyer AJ: A trial of therapy versus supportive therapy for social anxiety disorder. Depression and Anxiety 25 (6): 542-553, 2007.
  237. Blanco C, Patel SR, Liu L, Jiang H, Lewis-Fernandez R, Schmidt AB, Liebowitz MR, Olfson M: National trends in ethnic disparities in mental health care.  Medical Care 45(11): 1012-9, 2007
  238. Schneier FR, Martinez D, Abi-Dargham A, Zea-Ponce Y, Simpson HB, Liebowitz MR, Laruelle M: Striatal dopamine D2 receptor availability in OCD with and without comorbid social anxiety disorder: Preliminary findings. Depression and Anxiety 25 (1): 1-7, 2008.
  239. Choy Y, Schneier FR, Heimbert RG, Ok KS, Liebowitz MR: Features of the offensive subtype of Taijin-Kyofu-Sho in U.S. and Korean patients with DSM-IV social anxiety disorder.  Depression and Anxiety 25 (3): 230-240, 2008
  240. Pollack M, Endicott J, Liebowitz MR, Russell J, Detke M, Spann M, Ball S, Swindle R: Examining quality  of life in patients with generalized anxiety disorder: Clinical relevance and response to duloxetine treatment. Journal of Psychiatric Research 42 (12): 1042-1049, 2008.<br>
  241. Schechter DS, Coates SW, Kaminer T, Coots T, Zeanah CH, Davies M, Marshall RD, Liebowitz MR, Trabka KA, McCaw J, Myers MM: Distorted maternal mental representations and atypical behavior in a clinical sample of violence-exposed mothers and their toddlers. Journal of Trauma and Dissociation 9: 123-147, 2008. 
  242. Simpson HB, Petkova E, Cheng J, Huppert H, Foa EB, Liebowitz MT: Statistical models can affect inferences from clinical trials: A case study from obsessive compulsive disorder research. Journal of Psychiatric Research 42 (8): 631-8, 2008.
  243. Simpson HB, Foa EB, Liebowitz MR et al: A randomized controlled trial of cognitive behavioral therapy for augmenting pharmocotherapy in obsessive compulsive disorder.  American Journal of Psychiatry 165: 621-630, 2008. 
  244. Blanco C, Olfson M, Goodwin RD, Ogburn E, Liebowitz MR, Nunes EV, Hasin DS: Generalizability of clinical trials for major depression to community samples: Results from the National Epidemiologic Survey on Alcohol and Related Conditions.  Journal of Clinical Psychiatry 69 (8): 1276-80, 2008.
  245. Liebowitz MR, Manley AL, Padmanabhan SK, Ganguly R, Tummala R, Tourian K: Efficacy, safety and tolerability of desvenlafaxine 50 mg/d and 100 mg/d in outpatients with major depressive disorder. Current Medical Research and Opinion 24 (7): 1877-90, 2008.
  246. Fallon BA, Petkova E, Vermes D, Skritskaya N, Sanchez-Lacay A, Chenk J, Schneier F, Campeas R, Liebowitz MR: A double-masked placebo controlled study of fluoxetine in hypochondriasis. Journal of Clinical Psychopharmacology 2008; 28:638-645.
  247. Ross S, Fallon B, Petkova E, Feinstein S, Liebowitz MR: Long term (4-11 year) follow-up study of patients with refractory OCD. Journal of Neuropsychiatry and Clinical Neurosciences 2008; 20 (4): 450-457).
  248. Huppert JH, Simpson HB, Nissenson K, Foa EB, Liebowitz MR et al: Quality of life and functional impairment in obsessive compulsive disorder: A comparison of patients with and without comorbidity, patients in remission, and healthy controls. Depression and Anxiety 2009; 26(1): 39-45.
  249. Rytwinski NK, Fresco DM, Heimberg RG, Coles ME, Liebowitz MR, Cissell S, Stein MB, Hoffman SG: Screening for social anxiety disorder with the self-report version of the Liebowitz Social Anxiety Scale. Depression and Anxiety 2009; 26 (1): 34-38.
  250. Schneier FR, Abi-Dargham A, Martinez D, Slifstein M, Hwang, DR, Liebowitz MR, Laruelle M: Dopamine transporters, D2 receptors, and dopamine release in social anxiety disorder.  Depression and Anxiety 2009; 26:411-418.
  251. Liebowitz MR, Asnis G, Mangano R, Tzanis E: A double blind, placebo controlled, parallel group, flexible dose study of venlafaxine extended-release capsules in adult outpatients with panic disorder. Journal of Clinical Psychiatry 2009; 70(4): 550-561.
  252. Adler L, Liebowitz MR, Kronenberger W, Qiao M, Rubin R, Hollandbeck M, Deldar A, Schuh K, Durell T: Atomoxetine treatment in adults with attention deficit/hyperactivity disorder and comorbid social anxiety disorder. Depression and Anxiety 2009; 26 (3): 212-221. 
  253. Stein MB, Ravindran LN, Simon NM, Khan A, Liebowitz MR, Brawman-Mintzer O, Lydiard RB, Pollack M: A multi-center, randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy and safety of levetiracetam for treatment of generalized social anxiety disorder. Journal of Clinical Psychopharmacology (In review).
  254. Liebowitz MR, Salman E, Mech A, Dunner D, Pratap R, Johnson AE: Ziprasidone monotherapy in bipolar II depression: An open trial. J Affective Disorders 2009; 118: 205-208.
  255. Blanco C, Heimberg RG, Schneier FR, Fresco DM, Chen H, Turk CL, Vermes D, Erwin BA, Schmidt AB, Juster H, Campeas R, Liebowitz MR: A placebo-controlled trial of phenelzine, cognitive behavioral group therapy and their combination for social anxiety disorder. Archives of General Psychiatry 2010; 67: 286-295.
  256. Maher M, Huppert JD, Chen H, Duan N, Foa EB, Liebowitz MR, Simpson HB: Moderators and predictors of response to cognitive-behavioral therapy augmention of pharmacotherapy in obsessive compulsive disorder.  (In press, Psychological Medicine).
  257. Liebowitz MR, Tourian: Efficacy, safety and tolerability of desvenlafaxine 50 mg/day for the treatment of major depression (Primary Care Companion to J Clinical Psychiatry 2010 (12 (3) ii pcc.09roo845.
  258. Durell T, Adler L, Liebowitz M, Rubin R, Qiao M, Hollandbeck M, Deldar A, Glaser P, Kronenberger W:  An 8 week open label extension period study of atomoxetine with attention deficit/hyperactivity disorder and comorbid social anxiety disorder. Journal of  ADHD and Related  Disorders 2010; 1(3): 36-52.
  259. Liebowitz MR, Lam RW, Lepola U, Datto C, Sweitzer D, Eriksson H: Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy as maintenance treatment of major depressive disorder (MDD): A randomized, placebo-controlled trial. Depression and Anxiety 2010; 27:964-976.
  260. Bruce LC, Heimberg RG, Blanco C, Schneier FR, Liebowitz MR: Childhood maltreatment and social anxiety disorder: Implications for symptom severity and response to pharmacotherapy.  Depression and Anxiety 2011 Nov 7 doi: 10.1002/da.20909. (Epub ahead of print),
  261. Schneier FR, Rodebaugh TL, Blanco C, Lewin H, Liebowitz MR. Fear and avoidance of eye contact in social anxiety disorder. Comprehensive Psychiatry 2011; 52(1): 81-87.
  262. Xu Y, Scheier FR, Heimberg RG, Princisvalle K, Liebowitz MR, Wang S, Blanco C. Gender differences in social anxiety disorder: Results from the national epidemiological sample on alcohol and related conditions. Journal of Anxiety Disorders, 2011; Oct 7 E pub ahead of print
  263. Rodebaugh TL, Heimberg RG, Brown PJ, Fernandez KC, Blanco C, Schneier FR, Liebowitz MR: More reasons to be straightforward: Findings and norms for two scales relevant to social anxiety disorder. Journal of Anxiety Disorders 2011; 25(5):623-630.
  264. Foa EB, Simpson HB, Liebowitz MR, Williams M, Powers MB, Cahill S, Franklin M, Chang-Gyu H, Campeas R, Rosenfield D, Schmidt AB: Augmenting SRI treatment with exposure and ritual prevention (EX/RP) for obsessive compulsive disorder: Long term outcome. Submitted for publication.
  265. Pinto A, Liebowitz MR, Foa EB, Simpson HB: Obsessive compulsive personality disorder as a predictor of exposure and ritual prevention outcome for obsessive compulsive disorder. In press Behavior Research and Therapy.
  266. Liebowitz MR, Tourian K, Hwang E, Mele L: A randomized, double blind, placebo controlled study of desvenlafaxine 10 and 50 mg,day: Efficacy and safety in depressed outpatients. Submitted for publication. 
  267. Shumaker EA, Rodebaugh TL, Heimberg RG, Blanco C, Schneier FR, Liebowitz MR: Perfectionism factors across measures using exploratory and confirmatory factor analysis in social anxiety disorder and non-clinical samples. Submitted for publication.
  268. Schneier FR, Heimberg RG, Liebowitz MR, Blanco C, Gorenstein L: Social anxiety and functional impairment in patients seeking surgical evaluation for hyperhidrosis. Submitted for publication.
  269. Williams MT, Farris SG, Franklin ME, Liebowitz MR, Simpson HB, Foa EB: The impact of symptom dimensions on outcome of exposure and ritual prevention for obsessive compulsive disorder. Submitted for publication.
  270. Liebowitz MR, Croft HA, Kajdasz DK, Whalen H, Gallipoli S, Athanasiou M, Reed CR: The safety and tolerability profile of vilazodone, a novel antidepressant for the treatment of major depression. Submitted for publication


Books:

  1.  Liebowitz MR: Chemistry of Love. Boston, Little Brown 1983.
  2. Klein DF, Liebowitz MR, Fyer AF, and Gorman JM (eds): Modern Problems of Pharmacopsychiatry (Volume 22): Anxiety. S. Karger A.G., Basel, Switzerland, 1987.
  3. Spiegel D, Liebowitz MR, and Nemiah J (eds): Anxiety Disorders, Dissociative Disorders, Adjustment Disorders.  In GO Gabbard (ed), Treatment of Psychiatric Disorders: The DSM-IV Edition.  Washington, DC, American Psychiatric Association Press, 1995.
  4. Heimberg RG, Liebowitz MR, Hope DA, and Schneier FR (eds): Social Phobia: Diagnosis, Assessment, and Treatment. New York City, Guilford Press, 1995.
  5. Ford E with Liebowitz MR, Wasner Andrews, L: What You Must Think of Me: A Firsthand Account of One Teenager’s Experience with Social Anxiety Disorder. New York City, Oxford University Press, 2007. 


Chapters:

  1.  Liebowitz MR and Klein DF:  Hysteroid dysphoria.  In HS Akiskal (ed), Affective disorders:  Special clinical forms. Psychiatric Clinics of North America, 2(3): 555-575, 1979.
  2. Liebowitz MR and Klein DF: Interrelationship of hysteroid dysphoria and borderline personality disorder.  In MH Stone (ed), Borderline disorders. Psychiatric Clinics of North America, 4(1): 67-87, 1981.
  3. Strain JJ, Liebowitz MR and Klein DF:  Anxiety and panic attacks in the medically ill. In JJ Strain (ed), The medically ill patient. Psychiatric Clinics of North America, 4(2): 333-350, 1981.
  4. Liebowitz MR and Klein DF:  Agoraphobia: Clinical features, pathophysiology and treatment.  In DL Chambless and AJ Goldstein (eds), Agoraphobia: Multiple Perspectives on Theory and Treatment, John Wiley and Sons, 1982, pp 153-181.
  5. Klein DF and Liebowitz MR:  Psychotherapeutic attitudes in the drug treatment of anxiety and phobic reactions.  In MH Greenhill and A Gralnick (eds), Psychopharmacology and Psychotherapy, MacMillan Publication Company, 1983, pp 145-164.
  6. Liebowitz MR:  Psychopharmacological intervention in personality disorders.  In J Frosch (ed), Personality Disorders, APA Monograph, 1983.
  7. Quitkin FM, Schwartz D, Liebowitz MR, Stewart JW, McGrath PJ, Harrison W, Halpern F, Puig-Antich J, Tricamo E, Sachar EJ, and Klein DF:  Atypical depressives:  A preliminary report of antidepressant response and sleep patterns and cortisol secretion.  In PJ Clayton and JE Barrett (eds), Treatment of Depression: Old Controversies and New Approaches, New York, Raven Press, 1983, pp 253-263.
  8. Liebowitz MR:  The efficacy of antidepressants in DSM-III anxiety disorders.  In L Grinspoon (ed), Psychiatry Update, The American Psychiatric Association Annual Review, Volume III, Washington, DC, American Psychiatric Press, 1984, pp 503-519.
  9. Liebowitz MR, Karoum F, Quitkin FM, Stewart J, McGrath PJ, Harrison W, Davies SO, and Klein DF:  Biochemical effects and antidepressant mechanisms of l-deprenyl.  In AA Boulton, GB Baker, WG Dewhurst, and M Sandler (eds), Neurobiology of Trace Amines, Clifton, NJ, Humana Press, 1984, pp 581-587.
  10. Gorman JM, Liebowitz MR, and Klein DF:  Panic disorder and agoraphobia. In Current Concepts in Medicine.  Kalamazoo, MI, Upjohn Company, 1984.
  11. Liebowitz MR, Klein DF, Quitkin FM, Stewart JW, and McGrath P:  Clinical implications of diagnostic subtypes of depression. In RM Post and JC Ballenger (eds), Neurobiology of the Mood Disorders, Baltimore, Williams and Wilkins Company, 1984.
  12. Gorman JM and Liebowitz MR: Panic and anxiety disorders. In JD Cavenor (ed), Psychiatry, New York, Lippincott, (1) 32:1-13, 1985.
  13. Liebowitz MR, Fyer AJ, Gorman JM, Campeas R, Levin A, Davies SO, and Klein DF: Alprazolam in the treatment of panic disorders. In MH Lader and HC Davies (eds), Drug Treatment of Neurotic Disorders: Focus on Alprazolam, Churchill Livingstone, 1985, pp 173-177.
  14. Gorman JM, Fyer MR, Liebowitz MR, and Klein DF:  Lactate provocation of panic.  In C Shagass (ed), Biological Psychiatry, Elsevier Press, 1986, pp 639-641.
  15. Liebowitz MR, Stone MH, and Turkat ID:  Treatment of personality disorders.  In RE Hales and AJ Frances (eds), The American Psychiatric Association Annual Review: Vol. V, Washington, DC, American Psychiatric Press, 1986, pp 356-393.
  16. Liebowitz MR, Quitkin FM, Stewart JW, McGrath PJ, Harrison W, Rabkin J, Tricamo E, Markowitz JS, and Klein DF:  Treatment of atypical depression:  Phenelzine, imipramine and placebo.  In H Hippius (ed), New Results in Depression Research, Heidelberg, Springer-Verlag, 1986, pp 112-117.
  17. Liebowitz MR:  Social phobia.  In DF Klein, Gorman JM, Fyer AF, and Liebowitz MR (eds), Modern Problems of Pharmacopsychiatry: Anxiety, Basel, Switzerland, Karger Publishing, 1987.
  18. Liebowitz MR:  Annotated bibliography of DSM-III anxiety disorders. In RL Spitzer and JBW Williams (eds), Diagnostic and Statistical Manual of Mental Disorders, 3rd Edition, DSM-III-R, American Psychiatric Association, 1987.
  19. Gorman J, Fyer MR, Liebowitz MR, and Klein DF:  Pharmacologic provocation of panic attacks.  In H Meltzer (ed), Psychopharmacology: The Third Generation of Progress, New York, Raven Press, 1987, pp 985-993.
  20. Liebowitz MR and Strauman TJ: Social Phobia. In JG Howells (ed), Modern Perspectives in Psycho-Social Pathology, New York, Brunner-Mazel, 1988, pp 203-220.
  21. Papp LA, Gorman JM, and Liebowitz MR:  Social phobia.  In R Noyes, M Roth and GD Burrows (eds), Handbook of Anxiety, Volume 2: Classification, Etiological Factors and Associated Disturbances, Elsevier, 1988, pp 341-364.
  22. Hollander E, Liebowitz MR, and Gorman JM:  Anxiety disorders.  In JA Talbott, RE Hales, and SG Yudofsky (eds), Textbook of Psychiatry, Washington, DC, American Psychiatric Press, 1988, pp 443-491.
  23. Levin AP and Liebowitz MR:  Biological factors of anxiety.  In GD Burrows, R Noyes and M Roth (eds), Handbook of Anxiety, Volume 1: Biological, Clinical & Cultural Perspectives, Amsterdam, Elsevier Science Publishers, 1988, pp 157-192.
  24. Liebowitz MR:  Pharmacotherapy of personality disorders.  In M Clyners and J Panksepp (eds), Emotions and Psychopathology, New York, Plenum Press, 1988, pp 77-94.
  25. Liebowitz MR:  Panic disorder and agoraphobia.  In RE Rakel (ed), Conn's Current Therapy, WB Saunders Publishers, 1989, pp 1006-1007.
  26. Levin AP, Schneier FR, and Liebowitz MR:  Social phobia. In R Heimberg (ed), Biology and Pharmacology. Clinical Psychology Review, 9:129-140, 1989.
  27. Liebowitz MR:  Somatic therapy of patients with DSM-III personality disorders.  In TB Karasu (ed), Treatment of Psychiatric Disorders, V3, Washington DC, APA Press, 1989.
  28. Hollander E, Levin AP, and Liebowitz MR:  Biological tests in the differential diagnosis of anxiety disorders. In J Ballanger and Post (eds), Clinical Aspects of Anxiety Disorders, New York, Wiley-Liss, 1990, pp 31-46.
  29. Welkowitz LA and Liebowitz MR:  Pharmacotherapy treatment of social phobia and performance anxiety.  In G Burrows, R Noyes, and M Roth (eds), Handbook of Anxiety, Volume 4, Amsterdam, Elsevier, 1990, pp 233-253.
  30. Fyer AJ, Liebowitz MR, and Klein DF: Treatment trials, comorbidity, and syndromal complexity. In JD Maser and CR Cloninger CR (eds), Comorbidity of Mood and Anxiety Disorders, Washington, DC, American Psychiatric Press, 1990, pp 669-679.
  31. Schneier FR and Liebowitz MR:  Social phobia in adulthood.  In M Hersen and C Last (eds), Handbook of Child & Adult Psychopathology: A Longitudinal Perspective, New York, Pergamon Press, 1990, pp 169-180.
  32. Schneier FR, Levin AP, and Liebowitz MR:  Pharmacological treatment of social phobia.  In AS Bellack and M Hersen (eds), Comparative Handbook of Treatments for Adult Disorders, J Wiley and Sons, 1990, pp 219-239.
  33. Hollander E and Liebowitz MR: Generalized anxiety disorders & panicogenic syndromes.  In  DG Byrne and R Rosenman (eds), Anxiety and the Heart, New York, Hemisphere Publishing, 1990, pp 53-72.
  34. Hollander E and Liebowitz MR:  Neuropsychiatric and neuropsychological studies of obsessive compulsive disorder.  In J Zohar and TR Insel (eds), Obsessive-Compulsive Disorder, New York, Springer Publishing, 1991, pp 126-145.
  35. Liebowitz, MR:  Pharmacological management of social and simple phobias.  In W Coryell and G Winokur (eds), The Clinical Management of Anxiety Disorders, New York, Oxford University Press, 1991, pp 63-78.
  36. Liebowitz MR: Atypical depressions:  Serotonergic or Dopaminergic? In GB Cassano and HS Akiskal (eds), Royal Society of Medicine Services International Congress and Symposium Series No. 165, London, Royal Society of Medicine Services Limited, 1991, pp 121-123.
  37. Liebowitz MR, Hollander E, Campeas R, Rosen W, Gorman JM, and Fyer A: Obsessive compulsive disorder:  Psychobiological integration.  In J Zohar and TR Insel (eds), Obsessive- Compulsive Disorder, New York, Springer Publishing, 1991.
  38. Piacentini J, Jaffer M, Gitow A, Graae F, Davies S, Del Bene D, and Liebowitz MD: Psychopharmacologic treatment of child and adolescent obsessive compulsive disorder.  In Psychiatric Clinics of North America, 15(1): 87-107, 1992.
  39. Liebowitz MR:  Diagnostic issues in the anxiety disorders. In A Tasman and B Michealle (eds), American Psychiatric Press Review of Psychiatry, Washington, DC, APA Press, Volume 11, 1992, pp 247-259.
  40. Liebowitz MR:  Anxiety Disorders.  In FI Kass, JM Oldham, and H Pardes (eds), The Complete Home Guide to Emotional Problems and Mental Health, New York, Henry Holt and Company, 1992, pp 95-107.
  41. Gorman JM, Liebowitz MR, and Shear MK:  Panic and anxiety disorder.  In AM Cooper and R Michels (eds), Psychiatry, Revised Edition, New York, Lippincott, 1992.
  42. Frances A, Liebowitz MR, Widiger T, Pincus H, Manning D, and Davis W:  Moving towards the DSM-IV classification of anxiety disorders.  In MD Sachetti and GB Cassano (eds), Panic and Related Disorders: Current Knowledge and Perspectives, Lugano, Switzerland, Giardini Editors SA, 1993, pp 3-12.
  43. Fallon B, Rasmussen SA, and Liebowitz MR:  Hypochondriasis.  In E Hollander (ed), Obsessive-Compulsive Related Disorders, Washington, DC, American Psychiatric Press, 1993, pp 71-92.
  44. Liebowitz MR and Fyer AJ:  Diagnosis and clinical course of panic disorder with and without agoraphobia. In  BE Wolfe and J Maser (eds), Treatment of Panic Disorders: A Consensus Development Conference, Washington, DC, American Psychiatric Press, 1993, pp 19-30.
  45. Klein DF, Liebowitz MR, Gorman JM, and Lewis CP:  Evaluation of psychotropic drug treatment of panic-related disorders and social phobia.  In RF Prien and DS Robinson (eds), Clinical Evaluation of Psychotropic Drugs: Principles and Guidance, New York, Raven Press, 1994, pp 411-429.
  46. Gitow A, Liebowitz MD, and Schneier FR:  Monoamine oxidase inhibitor therapy of social phobia. In H Sidney and H Kennedy (eds), Clinical Advances in Monoamine Oxidase Inhibitor Therapies, Washington, DC, American Psychiatric Press, 1994, pp 225-254.
  47. Aronowitz B, Liebowitz MR, and Salmán E:  Clinical characteristics and psychopharmacological treatment of panic disorder. In S Friedman (ed), Anxiety Disorders in African-Americans, New York, Springer Publishing Company, 1994, pp 166-184.
  48. Montejo J and Liebowitz, MR:  Social phobia: Anxiety disorder comorbidity. In Bulletin of the Menninger Clinic, Topeka, KS, The Menninger Clinic, 1994, pp A21-A42.
  49. Barlow DH and Liebowitz MR:  Specific and social phobias.  In HI Kaplan and BJ Sadock (eds), Comprehensive Textbook of Psychiatry - VI, Williams & Wilkins, 1995, pp 1204-1218.
  50. Liebowitz MR and Marshall RD: Pharmacological treatment: Clinical Applications.  In R Heimberg, MR Liebowitz, DA Hope, and FR Schneier (eds), Social Phobia: Diagnosis, Assessment, and Treatment, Guilford Press, 1995, pp 366-383.
  51. Schneier FR, Liebowitz MR, Beidel DC, Fyer AJ, George MS, Heimberg RG, Holt CS, Klein DF, Levin AP, Lydiard RB, Mannuzza S, Martin LY, Nardi AE, Terrill DR, Spitzer RL, Turner SM, Uhde TW, Figueira IV, and Versiani M: Chapter 17: Social Phobia.  In Widiger TA, Frances AJ, Pincus HA, Ross R, First MB, & Davis WW (eds), DSM-IV Sourcebook, Volume 2, American Psychiatric Association, 1995, pp 507-548.
  52. Schneier FR, Liebowitz MR, Beidel D, Garfinkel R, Heimberg R, Juster H, Mannuzza S, Oberlander E, Turner SM, Law K, Mattia J, and Orsillo S:  McArthur data reanalysis for social phobia.  In Widiger TA, Frances AJ, Pincus HA, First MB, Ross R, Davis W (eds), DSM-IV, Source Book, Volume 4, Washington, DC, American Psychiatric Press, 1996.
  53. Liebowitz MR: Introductory to Section III: Anxiety disorders. In Widiger TA, Frances AJ, Pincus HA, First MB, Ross R, Davis W (eds), DSM-IV, Source Book, Volume 2, Washington, DC, American Psychiatric Association, 1996, pp 397-410.
  54. Liebowitz MR, Salmán E, Cárdenas D, Jusino C, and Davies S: Nosological comments on culture and mood and anxiety disorders.  In JE Mezzich, A Kleinman, H Fabrega, and DL Parron (eds), Culture and Psychiatric Diagnosis: A DSM-IV Perspective, Washington, DC, American Psychiatric Press, 1996, pp 131-133.
  55. Liebowitz MR and Heimberg RG:  Treatment of social phobia.  In SA Montgomery (ed), Social Phobia: A Clinical Review, Basel, Switzerland, World Psychiatric Association, 1996, pp 41-50.
  56. Salmán E, Diamond K, Jusino C, Sánchez-LaCay A, Liebowitz MR: Treatment of specific ethnic groups: Hispanic Americans. In S. Friedman (ed). Cultural Issues in the Treatment of Anxiety. Guilford Publications, New York, 1997, pp 59-80.
  57. Kozak MJ, Liebowitz MR, Foa EB: Cognitive Behavior Therapy and Pharmacotherapy for Obsessive-Compulsive Disorder: The NIMH-Sponsored Collaborative Study.  In Obsessive-Compulsive Disorder:  Contemporary Issues in Treatment.  WK Goodman, MV Rudorfer, and JD Maser (eds).  Lawrence Erlbaum Associates, Mahwah, New Jersey, 2000, pp 501-530.
  58. Blanco C, Schneier FR, Liebowitz MR:  Psychopharmacology.  In: Hoffman S and DiBartolo P (eds).  Social Anxiety to Social Phobia: Multiple Perspectives. Allyn & Bacon, 2001, pp 335-354.
  59. Blanco C, Schneier FR, Liebowitz MR: Pharmacological treatment of social phobia.  In: DJ Stein and E Hollander (eds).  APA Textbook of Anxiety Disorders.   American Psychiatric Publishing, 2002, pp 309-323.
  60. Liebowitz MR, Barlow D, Ballenger J, Davidson J, Foa EB, Fyer A, Koopman C, Kozak M, Spiegel D: Overview of the anxiety disorders.  DSM-IV Sourcebook. American Psychiatric Association Press, 2004.
  61. Blanco C, Garcia C, Liebowitz MR: Epidemiology and course. In: Bandelow B, Stein DJ, eds. Social Anxiety Disorder, New York: Marcel Dekker, 2004, pp 35-48.
  62. Simpson HB, Liebowitz MR: Combining Pharmacotherapy and Cognitive Behavioral Therapy in the Treatment of Obsessive Compulsive Disorder. In: Abramowitz J and Houts A (eds.). Concepts and Controversies in Obsessive Compulsive Disorder. Springer Science & Business Media, Inc., 2005.
  63. Blanco C, Raza MS, Schneier FR, Liebowitz MR. Pharmacotherapy of social anxiety disorder. In: Stein DJ, Lerer B, Stahl S, eds. Clinical Psychopharmacology: An Evidence Based Approach. Cambridge: Cambridge University Press, 2005, pp 137-164.
  64. Simpson HB, Liebowitz MR: Best Practice in Treating Obsessive Compulsive Disorder: What the Evidence Says. InThe Nature and Treatment of Pathological Anxiety, B. Rothbaum (Ed.) Guilford Publications, Inc. 2006.
  65. Blanco C, Schneier FR, Vega O, Liebowitz MR: Pharmacological treatment of social phobia.  In:  Stein DH, Hollander E and Rothbaum BO (eds).  APA Textbook of Anxiety Disorders, 2nd edition.  American Psychiatric Publishing, in press.
  66. Meany M, LeDoux J, Liebowitz M: Chapter on anxiety disorders for 3rd edition of Wiley Textbook of Psychiatry, in press.


Letters to the Editor:

  1.  Liebowitz MR and Klein DF:  Differential diagnosis and treatment of panic attacks and phobic states.  The Annual Review of Medicine, 32:583-599, 1981.
  2. Liebowitz MR:  Panic disorders:  Question the experts.  Journal of Clinical Psychopharmacology, 2(6): 4S-16S, 1982.
  3. Klein DF and Liebowitz MR:  Hysteroid dysphoria. Letter to the Editor.  American Journal of Psychiatry, 139(11): 1520-1521, 1982.
  4. Liebowitz MR:  The Biology of Anxiety. In RJ Matthew (ed), New York, Brunner-Mazel, 1982.  Book Review.  Psychosomatics, 24(9): 855, 1983.
  5. Levin AP, Liebowitz MR, Fyer AJ, Gorman JM, and Klein DF:  Lactate induction of panic: Hypothesized mechanisms and recent findings.  Biology of Agoraphobia, APA Monograph, 1984, pp 81-97.
  6. Liebowitz MR:  Imipramine in the treatment of panic disorder and its complications. Psychiatric Clinics of North America, 8(1): 37-47, 1985.
  7. Liebowitz MR, Gorman JM, Fyer AJ, Dillon D, and Klein DF: L'induction pharmacologique des crises de panique.  Les nouveaux aspects de l' Anxiete, Symposium International.  Actualites Medicales Internationales en Psychiatrie, 22:29S-34S, 1986.
  8. Levin AP, Fyer AJ, Gorman JM, Liebowitz MR, and Klein DF:  Troubles paniques.  Les nouveaux aspects de l' Anxiete, Symposium International.  Actualites Medicales Internationales en Psychiatrie, 22:90S-96S, 1986.
  9. Liebowitz MR:  Review of "Obsessive-compulsive disorder:  Psychological and pharmacological treatment."  Psychosomatics, 27(9): 670-671, 1986.
  10. Quitkin FM and Liebowitz MR:  Response to Dr. Paykel concerning, Phenelzine vs. Imipramine in Atypical Depression.  Letter to the Editor.  Archives of General Psychiatry, 43(6): 613-614, 1986.
  11. Liebowitz, MR:  Response to Dr. Ostow concerning, Social phobia:  Review of a neglected anxiety disorder.  Letter to the Editor.  Archives of General Psychiatry, 43(6): 614-615, 1986.
  12. Liebowitz MR:  Response to Dr. Gross' letter.  Questions and Answers Section, Journal of the American Medical Association, 257(5): 680, 1987.
  13. Liebowitz MR:  Commentary on the criteria for self-defeating personality disorder.  Journal of Personality Disorders, 1(2): 196-197, 1987.
  14. Liebowitz MR:  Commentary on the inner experience of the borderline self-mutilator.  Journal of Personality Disorders, 1(4): 325-327, 1987.  
  15. Liebowitz MR, Campeas R, and Hollander E:  Possible dopamine dysregulations in social phobia and atypical depression. Letter to the Editor.  Psychiatry Research, 22:89-90, 1987.
  16. Liebowitz MR:  Globus hystericus and panic attacks.  Letter to the Editor.  American Journal of Psychiatry, 144(3): 390-391, 1987.
  17. Liebowitz MR:  Tranylcypromine treatment of major depression.  Letter to the Editor. Journal of Clinical Psychiatry, 48(7): 303, 1987.
  18. Liebowitz MR:  Delineating social phobia. Letter to the Editor. British Journal of Psychiatry, 150:718-719, 1987.
  19. Liebowitz MR:  Commentary on Cloninger CR, A unified biosocial theory of personality and its role in the development of anxiety states.  Psychiatric Developments, 5(4): 385-387, 1987.  
  20. Liebowitz MR:  Review of "Obsessive Compulsive Disorder:  Theory and management, Edited by Jenike, Baer and Minichiello, The Hillside Journal of Clinical Psychiatry, 9(1): 120-122, 1987.
  21. Liebowitz MR:  Tricyclic therapy of the DSM-III anxiety disorders: A review with implications for further research.  Journal of Psychiatric Research, 22:7S-31S, 1988.
  22. Levin AP and Liebowitz MR:  Drug treatment of phobias: Efficacy and optimum use.  New Ethicals, 25(7): 125-146, 1988.
  23. Hollander E, Papp L, Campeas R, DeCaria C, and Liebowitz, MR:  More on self mutilation and obsessive compulsive disorder.  Letter to the Editor.  Canadian Journal of Psychiatry, 33(7): 674, 1988.
  24. Hollander E, Fay M, Klein DF, and Liebowitz MR:  Catecholaminergic and monoaminergic effects in OCD.  Progress in Catecholamine Research Part C: Clinical Aspects, New York, Alan R Liss, 1988, pp 377-384.
  25. Hollander E, Fay M, Klein DF, and Liebowitz MR: Clonidine and clomipramine in obsessive-compulsive disorder.  Letter to the Editor. American Journal of Psychiatry, 145(3): 388-389, 1988.
  26. Hollander Eand Liebowitz, M:  Augmentation of antiobsessional treatment.  Letter to the Editor. American Journal of Psychiatry, 145(10): 1314-1315, 1988.
  27. Liebowitz MR:  Dissociation and hypnotizability in posttraumatic stress disorder.  Letter to the Editor.  American Journal of Psychiatry, 145(11): 1486, 1988.
  28. Liebowitz MR: Prodromal symptoms in panic disorder with agoraphobia. Letter to the Editor.  American Journal of Psychiatry, 146:1084, 1989.
  29. Hollander E, Fairbanks J, DeCaria C, and Liebowitz MR:  Pharmacological dissection of panic and depersonalization.  Letter to the Editor. American J. of Psychiatry, 146:402, 1989.
  30. Liebowitz MR:  MAOI's in DST nonsupressors.  Letter to the Editor.  Journal of Clinical Psychiatry, 50:107, 1989.
  31. Hollander E, DeCaria C, and Liebowitz, MR:  Biological aspects of obsessive-compulsive disorder.  Psychiatric Annals, 19:80-87, 1989.
  32. Liebowitz, MR:  Antidepressants in panic disorders.  British Journal of Psychiatry, 155(6): 46S-52S, 1989.
  33. Liebowitz MR:  Medication treatment of obsessive-compulsive disorder.  Obsessive Compulsive Disorder Foundation Newsletter. June 1989.
  34. Liebowitz MR and Hollander E:  Lactate-induced anxiety.  Editorial.  Biological Psychiatry, 25:699-670, 1989.
  35. Hollander E, Liebowitz MR, and DeCaria C:  Conceptual and methodological issues in studies of obsessive-compulsive and Tourette's disorders.  Psychiatric Developments, 4:267-296, 1989.
  36. Hollander E, Fairbanks J, DeCari C, and Liebowitz MR: Derealization without depersonalization.  Letter to the Editor. American Journal of Psychiatry, 146:1360-1361, 1989.
  37. Liebowitz MR, Campeas R, Hollander E, and Fairbanks J:  Fluoxetine in adolescent obsessive-compulsive disorder.  Letter to the Editor.  American Journal of Psychiatry, 147:370-371, 1990.
  38. Liebowitz MR:  Response of alcoholic and nonalcoholic panic patients to lactate infusion. Letter to the Editor.  American Journal of Psychiatry, 147(6): 819, 1990.
  39. Hollander E, Neville D, DeCaria C, Mullen L, Schneier FR, and Liebowitz MR:  On dysmorphophobia misdiagnosed as obsessive-compulsive disorder.  Letter to the Editor. Psychosomatics, 31(4): 468, 1990.
  40. Hollander E, Liebowitz MR, DeCaria C, and Klein DF:  Fenfluramine, cortisol, and anxiety. Psychiatry Research, 31:211-213, 1990.
  41. Liebowitz MR, Hollander E, Schneier FR, Campeas R, Welkowitz L, Hatterer J, and Fallon B: Reversible and irreversible MAO inhibitors in other psychiatric disorders.  Acta Psychiatrica Scandinavia, 360:29S-34S, 1990.
  42. Hollander E, DeCaria C, Liebowitz MR, and Klein DF:  Body-dysmorphic disorder.  A Response.  American Journal of Psychiatry, 147(6): 816-817, 1990.
  43. Liebowitz MR, Ballenger J, Barlow DH, Davidson J, Foa EB, and Fyer A:  New perspectives on anxiety disorders in DSM-IV and ICD-10. Drug Therapy, Supplement, August 1990:129-136.
  44. Liebowitz MR and Fyer AJ:  Panic disorder: Approaches of DSM-IV.  Review.  Journal of Psychiatric Research, 24(1): 11-12, 1990.
  45. Hollander E, DeCaria CM, Saoud JB, Klein DF, and Liebowitz MR:  Further comments on neurological soft-signs in obsessive-compulsive disorder. A Reply. Archives of General Psychiatry, 48(3): 278-279, 1991.
  46. Sweet R, Liebowitz MR, Holt CS, and Heimberg RG:  Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.  Letter to the Editor.  Journal of Clinical Psychopharmacology, 11(5): 331-332, 1991.
  47. Liebowitz MR, Schneier FR, Hollander E, Welkowitz, Saoud JB, Feerick J, Campeas R, Fallon BA, Street L, and Gitow A: Treatment of social phobia with drugs other than benzodiazepines. Review.  Journal of Clinical Psychiatry, 52(11): 10S-15S, 1991.
  48. Fallon BA and Liebowitz MR:  Fluoxetine and extrapyramidal symptoms in CNS lupus.  Journal of Clinical Psychopharmacology, 11:147-148, 1991.
  49. Schneier FR, Chin SJ, Hollander E, and Liebowitz MR:  Fluoxetine in social phobia.  Letter to the Editor. Journal of Clinical Psychopharmacology, 12(1): 62-64, 1992.
  50. Liebowitz MR:  Borderline personality disorder and depression. Letter to the Editor.  American Journal of Psychiatry, 149(4): 581, 1992. 
  51. Liebowitz MR:  Dissociative experiences scale.  Letter to the Editor. American Journal of Psychiatry, 149(5): 719, 1992.
  52. Hollander E, Stein DJ, Saoud JB, DeCaria CM, Cooper TB, Trungold S, Stanley M, and Liebowitz MR: Effects of fenfluramine on plasma: HVA in OCD.  Psychiatry Research, 42:185-188, 1992.
  53. Graae FG, Gitow A, Piacentini JC, Jaffer M, and Liebowitz M: Response of OCD but not trichotillomania potent anti-serotonergic medication. Letter to the Editor.  American Journal of Psychiatry, 149(1): 149-150, 1992.
  54. Fallon BA, Liebowitz MR, and Klein DF: Taking chronic fatigue seriously.  Letter to the Editor. American Journal of Psychiatry, 149(12): 1752, 1992.
  55. Liebowitz MR:  Depression with anxiety and atypical depression. Journal Clinical Psychiatry, 54(2): 10-14, 1993.
  56. Liebowitz MR:  Proposed changes in DSM IV for anxiety disorders. In DL Dunner (ed), Current Psychiatric Therapy, Philadelphia, PA, WB Saunders, 1993, pp 261-262.
  57. Liebowitz MR:  Mixed anxiety and depression:  Should it be included in DSM-IV?  Journal of Clinical Psychiatry, 54(5): 4S-7S, 1993.
  58. Liebowitz MR:  Functional classification of anxiety-panic. Der Nervenarzt, 64(9): 7, 1993.
  59. Oberlander E and Liebowitz MR:  The pharmacology of stuttering: A critique. Letter to the Editor.  American Journal of Psychiatry, 150(2): 355, 1993.
  60. Liebowitz MR, Schneier F, Gitow A, and Feerick J:  Reversible MAO inhibitors in social phobia. Clinical Neuropharmacology, 16(5): 583-588, 1993.
  61. Liebowitz MR:  Pharmacotherapy of social phobia.  Journal of Clinical Psychiatry, 54(12): 31S-35S, 1993.
  62. Marshall RD, Schneier FR, Feerick J, Fallon BA, and Liebowitz MR:  Medication therapy for social phobia. Journal of Clinical Psychiatry, 55:33-37, 1994.
  63. Liebowitz MR and Barlow DH: Panic disorder: The latest on diagnosis and treatment. Review. Journal of Practical Psychiatry and Behavioral Health, 1(1): 10-19, 1995.
  64. Liebowitz MR et al.: Interim Analysis Clarification on CMI vs. BT in OCD.  Letter to the Editor.  Journal of Clinical Psychiatry, 56(9): 435, 1995.
  65. Marshall RD, Abbate L, Schneier FR, Fallon BA, and Liebowitz MR: Adverse events in PTSD patients taking fluoxetine.  Letter. American Journal of Psychiatry, 152:1238, 1995.
  66. Marshall RD and Liebowitz MR:  Bupropion/paroxetine combination treatment for refractory depression.  Letter to the Editor.   Journal of Clinical Psychopharmacology, 16(1): 80-81, 1996.
  67. Marshall RD, Stein DJ, Liebowitz MR, and Yehuda R: A pharmacotherapy algorithm in the treatment of posttraumatic stress disorder.  Psychiatric Annals, 26(14): 217-226, 1996.
  68. Schneier FR, Juster HR, Heimberg RG, and Liebowitz MR: Diagnosis and treatment of social phobia. Journal of Practical Psychiatry and Behavioral Health, 2:94-104, 1996.
  69. Liebowitz MR and Heimberg RG:  Issues in the design of trials for the evaluation of psychopharmacological treatments for social phobia.  International Clinical Psychopharmacology, 11(3): 49-53, 1996.
  70. Heimberg RG and Liebowitz MR: Issues in the design of trials for the evaluation of psychosocial treatments for social phobia.  International Clinical Psychopharmacology, 11(3): 55-64, 1996.
  71. Simpson HB and Liebowitz MR: Antidepressant-induced cycle acceleration in bipolar disorder.  Letter to the Editor.  American Journal of Psychiatry, 153(9): 1239, 1996.
  72. Fallon BA, Schneier FR, Marshall RD, Campeas R, Vermes D, Goetz D, and Liebowitz MR: The pharmacotherapy of hypochondriasis.  Psychopharmacology Bulletin, 32:607-611, 1996.
  73. Simpson HB, Hurowitz GI, Liebowitz MR.  General Principles in the pharmacotherapy of antidepressant-induced rapid cycling: A case series.  Journal of Clinical Psychopharmacology, 17(6): 460-466, 1997.
  74. Blanco C, Liebowitz MR: Dimensional versus categorical response to moclobemide in social phobia. Journal of Clinical Psychopharmacology, 18(4):344-6, 1998.
  75. Liebowitz MR: Update on the diagnosis and treatment of social anxiety disorder. Journal of Clinical Psychiatry, 60(18):22-26, 1999.
  76. Marshall RD, Spitzer R, Liebowitz M: Review and critique of the new DSM-IV diagnosis of acute stress disorder.  Author reply.  American Journal of Psychiatry, 157(11):1890-1891, 2000. 
  77. Marshall RD, Schneier FR, Lin S-H, Simpson HB, Vermes D, Liebowitz MR:  Reply to letter to the editor regarding the paperAChildhood Trauma and Dissociative Symptoms in Panic Disorder@ American Journal of Psychiatry, 158:656a-657a, 2001.


Case Reports:

  1.  Liebowitz MR, McGrath PJ and Bush SC:  Mania occurring during treatment for depersonalization: A report of two cases. Journal of Clinical Psychiatry, 41:33-34, 1980.
  2. Liebowitz MR and Klein DF:  Combining psychotherapy and drug therapy in the management   of the psychological disorders of women.  The Female Patient, 8(5): 25-29, 1981.
  3. Liebowitz MR:  Patient's dramatic moves swings presents challenge for the therapist. Case Report.  Hospital and Community Psychiatry, 34(4): 305-306, 1983.
  4. Liebowitz MR and Heimberg RG:  Treatment of social phobia.  Prepared for World Psychiatric Association Social Phobia Educational Program.
  5. Swinson R, Ballenger J, and Liebowitz MR:  Panic disorder, social phobia & depression:  The clinical interface.  Presented at the Canadian Psychiatric Association Annual Meeting, 1994.
  6. Fallon BA, Schwartzberg M, Bransfield R, Zimmerman B, Scotti A, Weber CA, and Liebowitz MR: Late stage neuropsychiatric Lyme Borreliosis: Differential diagnosis and treatment.  Psychosomatics, 36(3): 295-300, 1995.


Abstracts:

  1.  Liebowitz MR and Klein DF:  Antidepressant pharmacotherapy for agoraphobia, phobias, and panic states.  International Drug Therapy Newsletter, 15(8): 31-32, 1980.
  2. Stewart JW, Quitkin FM, Liebowitz MR, McGrath P and Klein DF: Efficacy of desipramine in mildly depressed patients: A double blind placebo-controlled trial.  Psychopharmacology Bulletin, 17(1): 136-138, 1981.
  3. Liebowitz MR and Klein DF:  Uses of MAO inhibitors for borderline patients.  In RO Friedel (ed), The Borderline Patient: Diagnosis and Management, 1981, pp 22-28. Proceedings from a symposium at the annual meeting of the APA, San Francisco, 1980.
  4. McGrath P, Quitkin FM, Stewart J, Liebowitz MR, Fyer AJ, Davies SO and Klein DF:  Novel antidepressants:  A clinical trial of mianserin.  Psychopharmacology Bulletin, 17(1):21-23, 1981.
  5. Liebowitz MR, Fyer AJ, McGrath P and Klein DF:  Clonidine treatment of panic disorder. Psychopharmacology Bulletin, 17(3): 122-123, 1981.
  6. Liebowitz MR, Quitkin FM, Stewart JW, McGrath PJ, Harrison W, Schwartz D, Rabkin J, Tricamo E and Klein DF:  Phenelzine and imipramine in atypical depression. Psychopharmacology Bulletin, 17(3): 159-161, 1981.
  7. Quitkin FM, Schwartz DG, Liebowitz MR, Stewart JW, McGrath PJ, Halpern F, Puig-Antich J, Tricamo E, Harrison W, Sacher EJ, and Klein DF:  Atypical depressives:  A preliminary report of antidepressant response and sleep patterns.  Psychopharmacology Bulletin, 18(1): 78-80, 1981.
  8. McGrath PJ, Quitkin FM, Blood D, Liebowitz MR, Stewart J, Fyer AJ and Klein DF:  The effect of mianserin on cardiac condition: A controlled study.  Psychopharmacology Bulletin, 8(1): 71-72, 1982.
  9. Stewart J, Quitkin FM, McGrath P, Liebowitz MR, and Klein DF:  Efficacy of mianserin in mildly depressed patients. Psychopharmacology Bulletin, 18(1): 68-70, 1982.
  10.  Liebowitz MR and Klein DF:  Unresolved issued in the treatment of agoraphobia with panic attacks. Psychopharmacology Bulletin, 18(4): 109-113, 1982.
  11. Liebowitz MR, Karoum F, Quitkin FM, Davies SO, Stewart JS, McGrath PJ, Harrison W, Schwartz D, Levitt M, Linnoila M, Wyatt R, Palij M and Klein DF:  Biochemical effects of deprenyl.  Psychopharmacology Bulletin, 19(3): 336-339, 1983.
  12. Liebowitz MR, Fyer A, Appleby I, Levitt M, Gorman J, Dillon D, Levy A, Anderson S, Davies SO, Palij M, and Klein DF:  Lactate provocation of panic attacks.  Psychopharmacology Bulletin, (3):476-478, 1983.
  13. Harrison WM, Cooper TB, Quitkin FM, Liebowitz MR, McGrath PJ, Stewart JW, and Klein DF: Tyramine sulfate excretion test in depressive illness.  Psychopharmacology Bulletin, 19(3): 503-504, 1983.
  14. Gorman JM, Levy GF, Liebowitz MR, McGrath P, Appleby I, Dillon DJ, Davies SO, and Klein DF: Intravenous propranolol during sodium lactate infusion.  Psychopharmacology Bulletin, 19(4): 577-578, 1983.
  15. Fyer AJ, Liebowitz MR, and Gorman JM:  Sodium lactate reinfusion of recovered lactate vulnerable panic disorder patients. Psychopharmacology Bulletin, 19(4): 576-577, 1984.
  16. Liebowitz MR, Gorman JM, Fyer AJ, Levitt M, Levy G, Dillon D, Appleby I, Anderson S, Palij M, Davies SO and Klein DF: Biological accompaniments of lactate-induced panic.   Psychopharmacology Bulletin, 20(1): 43-44, 1984.
  17. Liebowitz MR, Quitkin FM, McGrath P, Harrison W, Rabkin JG, Klein DF: Psychopharmacological dissection of nonendogenous depression.  Psychopharmacology Bulletin, 20(3):390-392, 1984.
  18. Liebowitz MR, Fyer AJ, Gorman JM, Dillon D, Appleby IL, Levy G, Anderson S, Levitt M, Palij M, Davies SO, and Klein DF: Provocation of panic attacks by sodium lactate infusion. Journal of Clinical Psychiatry, 2(1):18-20, 1984.
  19. Harrison W, Stewart J, Ehrhardt A, Rabkin J, McGrath P, Liebowitz MR, and Quitkin F:  A controlled study of the effects of antidepressant on sexual function.  Psychopharmacology Bulletin, 21(1):85-88, 1984.
  20. Liebowitz MR, Quitkin FQ and Klein DF:  Diagnosis and treatment of atypical depression. Currents in Affective Illness, 3(6):5-7, 1984.
  21. Fyer AJ, Liebowitz MR, and Gorman JM, Sodium lactate reinfusion of recovered lactate vulnerable panic disorder patients. Psychopharmacology Bulletin, 19(4):576-577, 1984.
  22. Liebowitz MR, Quitkin FM, Stewart JW, McGrath PJ, Harrison W, Rabkin JG, Tricamo E, Markowitz JS, and Klein DF:  Effect of panic attacks on the treatment of atypical depressives. Psychopharmacology Bulletin, 21(3):558-561, 1985.
  23. Liebowitz MR, Gorman JM, Fyer AJ, Campeas R, Levin A, Davies SO, and  Klein DF: Psychopharmacological treatment of social phobia. Psychopharmacology Bulletin, 21(3):610-614, 1985.
  24. Gorman JM, Dillon D, Fyer AJ, Liebowitz M R, and Klein DF:  The lactate infusion model. Psychopharmacology Bulletin, 21(3):428-433, 1985.
  25. Liebowitz MR, Fyer AJ, Gorman J, and Klein DF:  Recent developments in the understanding and pharmacotherapy of panic attacks.  Psychopharmacology Bulletin, 22(3):792-796, 1986.
  26. Gorman J, Liebowitz MR, Fyer AJ, Fyer M, and Klein DF:  Possible respiratory abnormalities in panic disorder. Psychopharmacology Bulletin, 22(3):797-801, 1986.
  27. Liebowitz MR:  Panic disorders update.  Psychiatry Letter, 4(5):25-28, 1986.
  28. Liebowitz MR, Quitkin FM, Stewart JW, McGrath PJ, Harrison WM, Markowitz JS, Rabkin JG, Tricamo E, Goetz DM, and Klein DF:  Comparison of phenelzine, imipramine and placebo in atypical depression.  Clinical Neuropharmacology, 9(54): 566, 1986.
  29. Liebowitz MR:  Lactate infusions in panic disorder.  Problems de Psychiatria Clinica, Excerpta Medica, Amsterdam, 4:1-4, 1986.
  30. Liebowitz MR:  Effects of DSM-III-R anxiety classification:  Impact on psychopharmacological trials.  Psychopharmacology Bulletin, 24(1): 21-24, 1988.
  31. Liebowitz MR:  Forum - Is there pharmacology of social phobia.  The Harvard Medical School, Mental Health Letter, February 1989.
  32. Liebowitz MR:  Tricyclic antidepressants and monoamine oxidase inhibitors in the treatment of panic disorder:  Brief review. Psychopharmacology Bulletin, 25:17-20, 1989.
  33. Liebowitz MR, Schneier FR, Campeas R, Gorman J, Fyer A, Hollander E, Hatterer J, and Papp L:  Phenelzine and atenolol in social phobia:  Psychopharmacology Bulletin, 26:123-125, 1990.